The problem with cephalosporins

Dancer, S., J.

doi:10.1093/jac/48.4.463

The problem with cephalosporins

Dancer, S., J. 2001-10-01 00:00:00 Abstract The cephalosporin antibiotics have become a major part of the antibiotic formulary for hospitals in affluent countries. They are prescribed for a wide variety of infections every day. Their undoubted popularity relies upon lesser allergenic and toxicity risks as well as a broad spectrum of activity. It is the latter feature, however, that encourages the selection of microorganisms that are resistant to these agents. There are long-term implications for the treatment and control of this heterogeneous group of superinfections. When clinicians evaluate a septic patient, it is understandable that they choose empirical therapy with a cephalosporin whilst awaiting microbiology and other tests, since bacterial identification and antimicrobial testing still usually require 24–48 h. The broad-spectrum capability of these drugs, however, encourages rapid overgrowth of some microorganisms that are neither eliminated nor inhibited by therapy. These organisms not only have pathogenic potential, they may also be multiply resistant to antibiotics. This review discusses the evidence that cephalosporin usage is the most important factor in the selection and propagation of microorganisms such as Clostridium difficile, methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, multiply resistant coliforms and vancomycin-resistant enterococci, the continuing increase of which threatens the future of antimicrobial therapy. Introduction Although widely accepted as broad-spectrum antibiotics, cephalosporins are not active against all the bacteria commonly isolated in a hospital microbiology laboratory.1 Organisms that are not inhibited by cephalosporin therapy consequently overgrow, with varying potential to cause infection.2,3 Some of these are instantly recognizable as pathogens; others, although originally regarded as commensal or of low risk status, have subsequently been shown to cause disease.4 Furthermore, there is an association between cephalosporin usage and the emergence of multiply-resistant organisms.2,5–9 Microorganisms selected by cephalosporin therapy include commensal organisms such as coagulase-negative staphylococci (CNS), Pseudomonas aeruginosa, enterococci and Candida albicans, and organisms of more established pathogenicity, e.g. Clostridium difficile, penicillin-resistant pneumococci, multiply-resistant coliforms and methicillin-resistant Staphylococcus aureus (MRSA). Some of these organisms are constitutively resistant to cephalosporins while others have acquired resistance, usually as part of a multiple resistance package. This review discusses the evidence for a link between cephalosporins and overgrowth of certain microorganisms, including those that are multiply resistant to antibiotics. Inherently resistant microorganisms Coagulase-negative staphylococci CNS are the most prevalent skin commensals. Hospitals are a source of CNS, which includes carriage by patients and staff,10–12 and a reservoir in the hospital environment.13 There appears to be a relationship between antibiotic usage and antibiotic resistances of CNS in hospitals.14,15 Isolates from patients are generally multiply-resistant due to the continued heavy exposure of the hospital, staff and patients to antibiotics.11,16 Patients newly admitted to hospital tend to acquire hospital CNS within hours of their admission, especially if prescribed antibiotic therapy.11,17,18 Experimental models show that the selective pressure exerted by broad-spectrum cephalosporins brings about a rapid overgrowth of staphylococci that are resistant to the antibiotics used.19 This is also seen clinically, as most antibiotic-resistant hospital CNS are resistant to methicillin and are therefore relatively unaffected by cephalosporins.20 They consequently proliferate upon and within patients receiving these antibiotics.17,18,21 This property is not exclusive to the cephalosporins, as any antibiotic could theoretically have the same effect.15,16 It is very difficult to rank antibiotics, let alone individual β-lactam agents, according to their selective ability, but there have been studies showing that methicillin resistance in CNS is significantly associated with therapeutic and prophylactic use of cephalosporins.15,18,22 Methicillin-resistant CNS encouraged by cephalosporin therapy may have clinical implications for some patients.6,17,18,22 CNS are commonly associated with infections of artificial prostheses, including plastic catheters, and will generate persistent low-grade infections unless the prosthesis is removed.23 Current management usually involves removal of such prostheses under glycopeptide cover, which increases the overall usage of these antibiotics.24 Many hospitals in developed countries consume large amounts of cephalosporin antibiotics, particularly in surgical departments as the preferred choice for prophylaxis.25 This is being questioned at the present time for some specialities, because of concerns about the increasing prevalence of methicillin-resistant staphylococci. Some centres are already advocating a change from first- and second-generation cephalosporins to glycopeptides, but this move may be premature for others.22,26,27 These antibiotics are both expensive and toxic, and their use has been discouraged following the emergence of glycopeptide-resistant enterococci (GRE) and more recently, glycopeptide intermediately resistant S. aureus (GISA).28,29 Oxidative non-fermentative Gram-negative bacilli P. aeruginosa is another common isolate from patients. Ceftazidime and some newer cephalosporins aside, most cephalosporins encourage overgrowth of this organism because it is inherently resistant to these agents.2,30 Consumption of cephalosporin antibiotics in a hospital is associated with an increase in the isolation of P. aeruginosa.31,32 Ceftazidime use itself leads to a significant reduction in susceptibility of P. aeruginosa to this antibiotic.5,9,33 If its use is subsequently restricted, the proportion of susceptible P. aeruginosa increases once again.5 Oral cephalosporins prescribed for urinary tract infections select for P. aeruginosa, which overgrows and may then mask the identity of the original pathogen.34 Repeat swabs consequently incite inappropriate treatment for an organism that is not necessarily the primary pathogen and may only be of low clinical significance. Therapy with second- or third-generation cephalosporins also encourages overgrowth of Stenotrophomonas maltophilia.31,35,36 This organism may require additional treatment, although therapy is difficult because it is often multiply resistant to antibiotics.37 Ceftriaxone or ceftazidime therapy selects resistant mutants from pre-existing susceptible strains of Pseudomonas.31,33,38 In addition, these resistant mutants may be able to secondarily transfer the capacity for extendedspectrum β-lactamases (ESBLs) into Enterobacteriaciae.38 There are few therapeutic options for infections caused by these strains, and the only effective oral agents (quinolones) are losing ground because of increasing resistance.39 Enterococci Enterococci are also associated with cephalosporin therapy.3,19,40–45 These faecal-type streptococci first provoked interest as emerging pathogens in both hospital and community in the 1980s.4 Most infection occurs in the urinary tract, but patients who have received, or are receiving, parenteral cephalosporins appear to be at risk from enterococcal infections in a variety of sites, including blood.3,43,45 This is because enterococci are inherently resistant to cephalosporins and are able to colonize gastrointestinal sites previously populated by cephalosporin-susceptible organisms.19,41,46 This is particularly well illustrated by current theories regarding colonization resistance.47 Prescribing an antibiotic that decreases colonization resistance of the alimentary canal allows increased population densities (overgrowth) of potentially pathogenic bacteria. This correlates with mucosal invasion followed by translocation to lymph nodes. Overgrowth may also be associated with development or acquisition of resistance to the antibiotic prescribed.47 The majority of healthy volunteers given cephalosporins acquire a substantially increased proportion of enterococci in the gastrointestinal tract.30,41,48 This is also seen in patients.44,45,49 Animal studies describe profound effects of cephalosporin agents on colonization resistance, although antibiotics other than cephalosporins are also implicated.50 It is difficult to apportion the effects of different antibiotics on colonization resistance because there are so few detailed studies specifically examining this. Some antibiotics, however, seem to be better able to maintain the status of the indigenous gastrointestinal flora than others.41,51 Patients tend to be more vulnerable than volunteers to changes in colonization resistance and enterococcal overgrowth precedes infection of the urinary tract, wounds, catheter sites and/or blood.3,43,45 As with Pseudomonas, therapeutic options for clinically significant isolates are limited, and management has been further complicated by an increase in resistance to amoxicillin and gentamicin.52 GRE are virtually untreatable,53 and are discussed further below. Clostridium difficile C. difficile has long been associated with a range of clinical diseases, from antibiotic-associated diarrhoea to pseudomembranous colitis. Overgrowth of C. difficile, with or without clinical symptoms, is not exclusively associated with cephalosporins and has been reported following administration of many other antibiotics.54 However, overgrowth occurs more commonly after cephalosporin therapy.19,41,55–57 Healthy volunteers given oral cephalosporins virtually all excrete C. difficile after 10 days of therapy.58 Treatment options for compromised patients usually include oral vancomycin or metronidazole, or both. Treatment failures occur frequently and precipitate the patient into and out of isolation, such is the propensity for spread of this spore-forming anaerobe.59 The organism may also be associated with outbreaks, which are debilitating to patients and costly for the hospital.57,60,61 There has been a substantial increase of C. difficile in the UK over the last decade.62 It is possible that the British Thoracic Society endorsement of cephalosporins as first-line treatment for community-acquired pneumonia has played some part in the increase of this organism.63–65 A recent review states that the association between cephalosporins and C. difficile overgrowth is now so well established that cephalosporins should not be prescribed in care of the elderly units.64 This view has already been successfully transcribed into clinical practice, whereby restriction of cephalosporin use has resulted in a decrease in the numbers of patients with C. difficile.66,67 Candida albicans Overgrowth is not solely a bacterial domain. C. albicans awaits any opportunity afforded by antibacterial therapy, yeast infections often following a course of antibiotics. Antibacterial therapy has consistently been shown to be a major independent risk factor for the development of systemic candidosis.68,69 By no means exclusive to treatment with cephalosporins, Candida overgrows following exposure to most antibiotics.19,30,41 It is those with the broadest spectrum of cover, however, that are more likely to encourage overgrowth.44 Quinolones and aminoglycosides, for example, do not induce candidosis as rapidly or as often as cephalosporins.70,71 When volunteers are given oral cephalosporins, most become colonized by yeasts within 2 or 3 days of starting therapy;30 in another study, a group given amoxicillin did not show any increase in colonization with Candida.19 Patients treated with cefaclor, cefalexin, cefradine, cefuroxime, ceftriaxone, latamoxef or ceftazidime have an increased risk of developing Candida.2,44 Volunteers receiving parenteral ceftriaxone also show an overgrowth of yeasts in faecal flora.48 Surgical patients treated with cephalosporins demonstrate increased colonization with Candida.72 Patients are commonly found to have Candida from a throat swab soon after cefotaxime is initiated. Such patients are also at risk of candiduria, especially if the patient is catheterized.73 Candidaemia may follow if colonization of superficial sites and/or the urine is ignored.68,74 The more sites growing Candida, the higher the risk of invasive candidosis.75 Treating clinically significant candidal overgrowth is difficult, especially when there are so few antifungal agents available. There has been a huge increase in infections due to Candida over the past 20 years76,77 and there is no sign that numbers are abating.78 In hospital patients, the rate of blood-stream infection due to Candida spp. increased by almost 500% during the 1980s.76,77 Whilst there may be several different reasons for this, including greater awareness, more clinical interventions and better laboratory techniques, the increasing amount of Candida mirrors the increasing use of cephalosporins introduced over this period. Recent trends in the aetiology of hospital-acquired infections There has been a major shift in the aetiology of hospital-acquired infections during the 1980s in contrast to the 1970s, that is, an increase in the laboratory isolation of CNS, Candida, S. aureus, enterococci, P. aeruginosa and Enterobacter between 1980 and 1986–1989.77,79 Taken as a whole, the shifts are away from more easily treated pathogens towards more resistant pathogens with fewer options for therapy.79,80 With the complexity and choice of antibiotic therapy nowadays, it is difficult to find specific evidence for the association of commensal overgrowth with the cephalosporin antibiotics alone. One study looked at hospital-acquired bacteraemia in an adult intensive care unit over 25 years (1971–1995).32 Here, the use of amoxicillin plus gentamicin was gradually replaced by cephalosporins as first-line choice for the treatment of bacteraemic patients. During the last 5 years of the study, the number of bacteraemias increased two-fold, largely owing to increased isolation of enterococci, CNS, intrinsically antibiotic-resistant Gram-negative organisms (particularly P. aeruginosa) and Candida. Whilst the cephalosporins were introduced in the early 1980s, their prescribing frequency did not equal that of gentamicin until the 1990s. The organisms highlighted are the same as those already mentioned as being associated with cephalosporin therapy. The authors attributed the change in the spectrum of organisms to the changes in antibiotics used over the time period studied.32 An additional study shows that if cephalosporin usage is reduced as part of an overall reduction in antimicrobial prescribing, there is a decrease in hospital-acquired infections, namely, enterococcal and selected Gram-negative bacteraemias, and MRSA and S. maltophilia colonization or infection.81 Others have documented the association of cephalosporins with staphylococci, enterococci, multiply-resistant Gram-negative bacilli, yeasts and C. difficile.2,82,83 The next section describes a group of multiply-resistant bacteria rapidly increasing in hospitals throughout the world. It appears that cephalosporin usage selects for and encourages propagation of these organisms. It is even possible that the cephalosporin antibiotics play a role in the molecular initiation of resistance for some. Microorganisms with acquired resistance Extended-spectrum β-lactamase-producing coliforms β-Lactamases are the major determinants of resistance to β-lactam antibiotics.84 All Gram-negative bacteria elaborate chromosomally mediated β-lactamase enzymes. These are typically low level in coliforms isolated from human-free environments but may be induced in a wide variety of species by exposure to β-lactam drugs.85,86 The prevalence of β-lactamases has forced pharmaceutical companies to seek alternative agents that are resistant to β-lactamase attack.87 Cefotaxime and ceftazidime were initially regarded as indestructible from plasmid-mediated β-lactamases, but this belief has since been shattered following a cascade of reports describing plasmid-mediated resistance to both of these drugs.88,89 There are now increasing numbers of plasmid-mediated ESBLs described every year. Almost all of them are derivatives of the well-known TEM and SHV-1 β-lactamases.90 Variants of these inactivate third-generation cephalosporins and monobactams, having arisen by spontaneous mutation and being only marginally different in amino acid sequence from the parent enzymes.1 An additional mechanism of resistance is the capture on plasmids of normally chromosomal genes from Enterobacter cloacae, Citrobacter freundii or P. aeruginosa, which can provide Klebsiella pneumoniae or Escherichia coli with resistance to α-methoxy-β-lactams (cefoxitin and cefotetan) as well as to oxyimino-β-lactams (cefotaxime, ceftriaxone and ceftazidime).91 A resistant organism isolated during therapy to one cephalosporin may thus demonstrate reduced susceptibility to other antibiotics, not necessarily within the same chemical class.92 Multiply-resistant coliforms are associated with high-level usage of cephalosporins, particularly cefotaxime, ceftriaxone and ceftazidime.5–9, 44, 87, 93–97 These antibiotics induce and select for ESBL coliforms (ESBLC).87,95,98 If cephalosporins are avoided, there is less chance of selecting these highly resistant bacteria, and coliform susceptibility rates rise.5,99 At a hospital in New York, multiply-resistant E. cloacae isolates from the intensive care unit increased dramatically between 1988 and 1990.97 As a response, use of ceftazidime was severely restricted in favour of piperacillin in combination with an aminoglycoside. Following this change, susceptibility of E. cloacae isolates to ceftazidime increased from 54% to 75%, whilst the total number of multiply-resistant E. cloacae fell. No other major changes in susceptibility patterns were seen.97 Some resistant coliforms merely colonize patients; others invade to cause infection.8 Yet other epidemic strains spread to cause outbreaks of virtually untreatable disease.100,101 The location of antibiotic resistance mechanisms on plasmids facilitates easy spread between species and genera, and is most likely to occur in the gastrointestinal tract.46,102 Some physicians have already recognized the fact that cephalosporin usage may play a role in the selection of ESBL and therefore prescribe amoxicillin in conjunction with an antibiotic of another class for first-line treatment of community-acquired pneumonias.87 Similarly, some surgeons have reverted to the ‘old-fashioned’ combination of amoxicillin and gentamicin for surgical patients.87 The latter combination is less likely to encourage overgrowth of susceptible enterococci, yeasts and C. difficile, than would occur if a cephalosporin was the antibiotic of choice.3,19,57,72 Hospitals contain a concentrated reservoir of resistant coliforms, but a dilute version exists in the community. The path between the hospital and the community runs both ways.103 Even patients with no prior hospital contact can display clinically significant infection with multiply-resistant coliforms.104 Critically ill patients in intensive care units rapidly acquire such organisms, even if not previously colonized, and a battle often ensues between microbiologist and organism for time to allow the patient to recover from initial pathology before succumbing to hospitalacquired resistant microbes. Penicillin-resistant pneumococci Clinically significant infection with penicillin-resistant pneumococci (PRP) is prevalent worldwide.105 At present, the median MIC for strains in the USA lies between 0.05 and 0.1 mg/L and is continuing to rise. Most infections with intermediately resistant pneumococci (MIC 0.1–1.0 mg/L penicillin) are treatable with increased doses of penicillin, but isolates are now showing high-level resistance (>2.0 mg/L).106 Some of these demonstrate resistance to third-generation cephalosporins, and this proportion is also increasing.106 PRP are associated with extensive prior antimicrobial therapy,107 particularly with β-lactam antibiotics.108–112 They may be selected at the infection site or in the nasopharynx.109 Resistant strains may even reside in the nasopharynx before treatment is initiated and are then encouraged by the antibiotic given. It is also possible that penicillinsusceptible strains are transformed in vivo to strains that have a lower susceptibility to penicillin.113 Any antibiotic in theory has the potential to select resistant strains provided that the local concentration of the drug is high enough to inhibit susceptible cells whilst encouraging a resistant subset.109 The risk of selection is increased if patients are under-dosed or given prolonged courses of antibiotics, or if drugs with inadequate activity against pneumococci are prescribed.114,115 The aminopenicillins have been widely regarded as being disproportionately responsible for selecting PRP, but this may be only because the emergence of this pathogen coincided with increased consumption of these antibiotics.116 It is entirely possible that increased prescribing of other antibiotics, e.g. cephalosporins, macrolides and co-trimoxazole, is equally or more important than aminopenicillins in the promotion of PRP.116–119 Studies examining the effect of antibiotics on the carriage of PRP are often flawed in their design and conclusions.109 Authors do not often calculate the relative selective pressures of different classes of antibiotics;117–119 in many studies, investigators fail even to identify the specific antibiotics given, referring only to the generic term ‘antibiotics’.109 Even more unusually, some authors identify the classes of antibiotics that select resistant strains, but fail to complete the analysis. In one of these studies, co-amoxiclav was shown to be associated with a minimal increase in the incidence of PRP carriage (from 14% to 16%) whilst the use of other unidentified antibiotics was associated with a much greater increase in PRP incidence (from 39% to 70%).120 It is indisputable that aminopenicillins promote the carriage of PRP, because in common with other β-lactams, they select PRP strains already present in the oropharynx. It is also the case that there are other penicillin-resistant streptococci present in the oral cavity, which could serve as reservoirs for resistance genes that lead to alterations in pneumococcal penicillin-binding proteins (PBPs).121 There are some studies that detail a connection between cephalosporins and PRP.2,105,109,122–124 One compares the efficacy of cefixime versus co-amoxiclav in children with acute otitis media.124 Cefixime was associated with a rate of selection of PRP of 41.9%, compared with 15.9% for co-amoxiclav.124 The selection of PRP by oral cephalosporins, both in vitro and in vivo, can be explained by their reduced activities against PRP, as well as by the fact that the modification of a single penicillin-binding protein, PBP 2x, may result in a marked increase in MICs.124–126 Selection by cephalosporins occurs at higher frequencies than that by amoxicillin.125 Even very potent broad-spectrum cephalosporins are capable of selecting PRP.117 In a study whereby a single dose of ceftriaxone was compared with a 10 day course of co-amoxiclav for children with acute otitis media in an area of high PRP prevalence, nearly twice as many PRP were selected by the cephalosporin as by co-amoxiclav (27.4% and 14.5%, respectively).117 Other work indicates that oral cephalosporins promote mutants with higher MICs of parenteral third-generation cephalosporins than of penicillin.105 Oral cephalosporins are often prescribed for streptococcal pharyngitis, where colonizing pneumococci normally reside. Use of these agents may be responsible for the sudden increase in PRP recorded by a community survey in Northern Ireland;127 consumption has certainly been correlated with the prevalence of high-level penicillin resistance in Spain.128 The inference is, therefore, that cephalosporins select for and encourage resistance to β-lactam antibiotics in pneumococci colonizing the oropharynx.109 Furthermore, PRP have greater potential to spread than susceptible strains.129 Concurrent resistance to other antibiotics, including macrolides and co-trimoxazole in multiply-resistant strains, will not only select still greater numbers of resistant populations in the nasopharynx, but may also lead to clinical failures, thereby increasing the risk of dissemination of PRP.130 The pathogenicity of this organism is such that the increasing incidence worldwide is of major concern to clinicians. MRSA The prevalence of MRSA is also giving cause for concern.131S. aureus itself has always been regarded as a pathogen and now there are only a few remaining antibiotics effective against resistant strains. Potential usage of any member of the β-lactam group is excluded once S. aureus becomes resistant to methicillin.1 There is a steady increase of new cases nationally and an increasing proportion of MRSA from total numbers of staphylococcal bacteraemias.132 MRSA was first described in 1961 in Britain, but despite fear of spread, there were only sporadic outbreaks in the 1960s and 1970s.133–135 Cephalosporins were widely introduced in 1980 and the first epidemics of MRSA were reported in London during the middle 1980s.136 By 1990, most parts of the UK were affected. The Japanese experience cites the introduction of second- and third-generation cephalosporins in the early 1980s as playing a significant part in the emergence and spread of MRSA in Tokyo hospitals.137–139 The steady increase of MRSA in Europe, including Britain and Italy, has also been attributed to the use of cephalosporins.40,122,135,140–142 A report from America describes a community outbreak of MRSA among iv drug abusers who self-administered cephalosporins for prophylactic purposes.143 At least three mechanisms account for methicillin resistance in S. aureus: production of PBP 2a or 2′ encoded by the chromosomal mec(A) gene, production of modified PBPs and inactivation of methicillin by β-lactamase.144 There is insufficient evidence to prove the molecular role played by antibiotics in the acquisition of these mechanisms but it is widely believed that antibiotics are asso- ciated with the induction, selection and propagation of MRSA.137,138,140,145–151 The induction hypothesis originates firstly from training procedures, whereby methicillinsusceptible S. aureus (MSSA) is cultured in broth containing sub-MIC levels of β-lactam antibiotics, in particular, cefazolin and ceftizoxime.138 It is possible to create MRSA (MIC > 1000 mg/L) from such experiments, although rather more difficult to transpose them into a clinical context. Methicillin-resistant clones can also be identified from S. aureus specifically resistant to cephamycin antibiotics,146 and serial exposure of S. aureus to cefalexin discs induces the development of staphylococci cross-resistant to cefalexin and methicillin.152 The latter work also showed that once induced, the capacity for methicillin resistance was not easily lost.152 Considering selection, some authors specifically cite cephalosporin therapy as a major factor in the appearance of MRSA.149–151 Once established, continued use of cephalosporins encourages the spread of the organism.137,151 It is reasonable to assume that all members of the β-lactam class of antibiotics have some ability to induce methicillin resistance in staphylococci, albeit difficult to prove.152 It is even more difficult to apportion the ability for the selection process between individual β-lactam agents.15,153 If the capacity for generating MRSA is regarded as similar between β-lactam agents, however, then cephalosporins shoulder much of the responsibility owing to the frequency of their use. There are further issues that may be important in the evolution of MRSA. We may accept that the most plausible hypothesis is repeated exposure of S. aureus to β-lactam antibiotics,152,154 but it is also possible that inadequate doses, or too short a course, of the same agents may fail to eradicate infection with MSSA whilst presenting the β-lactam ring to the organism as a template or trigger. Poor prescribing, or non-compliance on the part of the patient, would encourage bacterial mutation to produce effective resistance mechanisms or, more likely, facilitate the clonal expansion of a member of the population already with the genetic capabilities for methicillin resistance.154 But these are probably not the only factors by which MSSA becomes MRSA. It is also possible that the methicillin resistance genes are transferred to S. aureus from Staphylococcus epidermidis.138,155,156 Antibiotic resistance characteristics can be transferred between coagulase-negative and coagulase-positive staphylococci and this includes methicillin resistance.156 Most hospitals have endemic methicillin-resistant S. epidermidis (MRSE) in the environment as well as colonizing staff and patients,10,12,13,157 and newly admitted patients soon become colonized with multiply-resistant CNS.11,12,16,17 Patients may even be admitted with MRSE on the skin at the proposed operation site, which, the authors suggested, should question the use of prophylactic cephalosporins.22 This particular study concerned patients admitted for prosthetic hip implants, in whom it was shown that the most common post-operative infections were caused by methicillin-resistant coagulase-negative staphylococci.22 The consequence of cephalosporin prophylaxis is illustrated by two clinical studies of surgical patients, the first of which showed that MRSE was detected in high numbers on the skin of surgical patients within 5 days of exposure to per-operatively administered cephalosporins.18 The second showed that just three doses of cefuroxime encouraged the appearance of MRSE from aortic graft recipients within 1 week.158 Once colonized, further usage of β-lactam antibiotics exerts the selection pressure required for continued increase in methicillin-resistant staphylococci.14,15,137,147,151 As it is the case that all persons are colonized with S. epidermidis and one in three persons are colonized with S. aureus, the propensity for selection and spread of methicillin-resistant staphylococci and the potential for genetic exchange between staphylococcal species becomes immediately apparent.137,155,156 There is a direct association between MRSA and cephalosporins. Asensio et al.159 showed that patients who had received treatment for >5 days with cephalosporins were three times more likely to acquire MRSA than those who had not received these agents. This agrees with other studies, which detail a significant association of cephalosporins with the acquisition of MRSA.149–151,160 Conversely, a study demonstrating the effects of reducing cephalosporin usage in three acute medical wards for the elderly showed that the number of MRSA infections was reduced by half; there was also a 42% drop in the number of C. difficile infections.66 Another reported a decline in the number of MRSA isolates from 35% to 23%, following the introduction of control strategies including a decision to decrease the use of cephalosporins in favour of piperacillin– tazobactam.161 MRSA appears to be a sensitive indicator of the quality of hospital hygiene overall,162 as it is associated with other hospital organisms of concern.66,81,161 If a hospital manages to control MRSA, it controls other hospital organisms as well.162 Recently, there has been a report published detailing the deaths of four children from MRSA infections, three of whom had originally received a cephalosporin.163 Cephalosporins are only poorly active against MRSA;164–166 it is possible that usage of these antibiotics not only selects for MRSA, but encourages enhanced virulence.151,161 Certainly, prophylactic cefazolin is a risk factor for deep surgical wound infections with borderline oxacillin-susceptible strains of S. aureus.167 GRE Enterococci have also become a significant cause of hospital-acquired infection over the past 20 years.4 Natural resistance to penicillin and cephalosporins has been further complicated by additional resistance to amoxicillin, co-amoxiclav, gentamicin and now glycopeptides.53,168 There are virtually no antibiotics available for the treatment of clinically significant resistant enterococci and no means whereby asymptomatic carriers can be cleared.28,169 The association between cephalosporin therapy and enterococcal overgrowth has already been discussed. It follows, therefore, that vancomycin-resistant enterococci (VRE) are also associated with cephalosporin usage.170,171 A recent report describes how hyperendemic VRE in a haematology unit was effectively eradicated by changing from ceftazidime to piperacillin–tazobactam as first-line treatment for febrile neutropenics. The reintroduction of ceftazidime was accompanied by a return of VRE, despite continued attention to hygiene and surveillance.170 A study previously mentioned witnessed a drop in the number of VRE isolates from 16% to 5% after restricting cephalosporins in favour of piperacillin–tazobactam.161 Outbreaks of VRE may be controlled by switching from cephalosporins to aztreonam,172 or from cephalosporins to aminoglycosides.173 VRE are also linked with the use of glycopeptides in hospitals151,168,174 and in animals,174,175 and this has been assumed to be the most important factor in the selection of these organisms.171 However, if the indications for vancomycin therapy are examined, it is apparent that some of these indications are actually generated by the use of cephalosporins,3,6,151,176 i.e. there is not only a direct association of cephalosporins with VRE, but an indirect one, whereby cephalosporins select other organisms that require treatment with vancomycin, which then leads to the selection of VRE.151 Methicillin-resistant staphylococci, for example, already linked to the widespread use of β-lactam antibiotics, including cephalosporins, warrant treatment with iv vancomycin for seriously infected patients.23,168,177 Even more vancomycin is used, for prophylactic purposes, if patients at risk are admitted to a hos- pital with endemic methicillin-resistant staphylococci.22,26 Glycopeptide-susceptible enterococci, selected by cephalosporin use, occasionally require treatment with vancomycin, especially if resistant to aminoglycosides.3,52 Patients with C. difficile colitis, another sequelae of cephalosporin therapy, also require treatment with vancomycin.171,178 Thus, cephalosporin use is associated with several different organisms, the management of which may include vancomycin. Increased vancomycin usage could then select for vancomycin-resistant organisms including VRE. The C. difficile scenario can be considered further regarding the evolution of VRE, because a patient treated with cephalosporin antibiotics suffers concurrent overgrowth of both C. difficile and enterococci.176,179 If severe diarrhoea ensues, therapy is usually with oral vancomycin. Thereby an abundance of naturally resistant enterococci are exposed to non-absorbable vancomycin and the gut provides an excellent site for selection.46 (Vancomycin-resistant pediococci, leuconostoc and lactobacilli inhabit the mouth, gut and genital tract, but these do not appear to be the source of the genes encoding acquired resistance in enterococci.180) When faeces are screened for VRE, those patients found to be positive are often colonized with C. difficile as well; some even have MRSA to complete the package.179 In summary, therefore, it may be that heavy usage of cephalosporins is the main driving force behind the increasing prevalence of VRE, rather than glycopeptides. This hypothesis is also supported by studies that report that parenteral vancomycin does not appear to be an important risk factor for acquisition of VRE,181,182 nor did the administration of copious amounts of oral vancomycin for an outbreak of C. difficile appear to generate a problem with VRE.173 Furthermore, successful restriction of vancomycin prescribing has had no effect upon the occurrence of VRE in some centres.183,184 An added complication regarding VRE in a hospital concerns its ability to survive long-term in the environment.185 It is worth promoting environmental hygiene in a hospital, especially since there are no effective protocols for clearing VRE from the human gastrointestinal tract.28,186 The hospital environment may not be so temperate as the human gut, but may still provide an appropriate medium whereby organisms are able to transfer resistance genes.187,188 Exchange of genes between Gram-positive organisms is well documented.189,190 MRSA is another organism noted for its ability to survive in the hospital environment, but there is no evidence that resistant enterococci have contributed towards the appearance of glycopeptide-tolerant strains of MRSA.191 In vitro studies on the pharmacodynamic effects of cephalosporins So far, this review has focused upon the problem of selection and overgrowth of organisms associated with cephalosporin therapy. A common theme underlying this problem is the inability of these antibiotics to eradicate effectively key organisms, thus encouraging survival either with or without enhanced resistance to antibiotics. In this context, recent work on the mechanism of action of cephalosporin antibiotics offers some in vitro explanations for these clinical observations.192 Microscopic studies on the effect of β-lactam antibiotics on the bacterial cell at concentrations in excess of the MIC are able to distinguish between amoxicillin and cefalexin.193 The sequence of events is inhibition of cell division followed by lysis; this occurs very quickly with amoxicillin, as cell growth barely reaches two cell units in length before the onset of lysis. With cefalexin, however, there is a significant period of filamentous growth before the cell lyses, usually as a result of a sudden rupture of the cell wall. Filaments can be observed in clinical specimens from patients with Gram-negative infections treated with a variety of β-lactams, and, in particular, the aminothiazolyl cephalosporins, e.g. cefuroxime, cefotaxime, ceftazidime and ceftriaxone. This property has prompted one author to state that bacterial growth is not actually inhibited by the filament-forming antibiotics and it follows that overall cell wall synthesis is not inhibited to any significant extent either.194 It could also be said that the time utilized for filament-forming by the cephalosporins is time available for antimicrobial resistance induction, whereas the use of other agents, which induce early cell death, would reduce the risk of such an event. Filamentous cells that develop in the presence of cephalosporins do eventually lyse as a result of a sudden rupture of the cell wall, usually at a point where cell division would normally have taken place.193 Round cell formation and rapid lysis can be achieved by using higher concentrations of predominantly filament-forming antibiotics.192,195 These antibiotics therefore do not precipitate the rapid cell lysis and bactericidal effects more usually associated with β-lactam agents, but promote the generation of aberrant forms that are able to survive in vivo. This may have clinical implications; first, as some bacteria may persist in patients following a course of one of these antibiotics; secondly, as survival may include the generation of tolerant or even resistant progeny, and thirdly, when assessing endotoxin release following exposure to antibiotics.196 Filament formation leads to a rapid increase in endotoxin production and, ultimately, endotoxin release when these cells lyse.197 There are several studies to support this.198–200 Higher doses of filament-forming antibiotics may alternatively produce the more fragile spheroplasts, which would tend to lyse and thus reduce the propensity for endotoxic shock.196,201 It is possible, therefore, that the choice and dose of an antimicrobial agent for a patient with septic shock could be clinically crucial.196 Conclusion This review has attempted to piece together some of the suspicions surrounding a very widely used class of antibiotics. There is strong suggestive evidence that cephalosporins have played a major role in encouraging the organisms discussed. Countries, and even individual hospitals, that have enforced low usage of cephalosporins through education, strict antibiotic policies and prescribing penalties, are currently experiencing relatively low rates of multiply-resistant organisms.66,135,141,142,161,202 Countries where cephalosporins are used more often have much higher rates of resistance.122,137,141,203 It is, however, difficult to determine whether it is specific restriction of cephalosporin antibiotics in isolation that is responsible for the lower rates of resistance, or, indeed, an overall effect from controlling all antibiotic classes.135 In defence of the former view, most of the references cited specifically target cephalosporins as key players in the link between antibiotic usage and prevalence of multiply-resistant organisms. Compounding the problem is the fact that microbiologists have yet to define fully the mechanisms linking antibiotic usage and antibiotic resistance. Prescribing colleagues will almost certainly question how just one group of antibiotics alone, within the extensive β-lactam class, could be the most important driving force behind the continuing increase in resistant organisms, even allowing for broad-spectrum activity and popularity.83,204,205 Convincing clinicians that antibiotic therapy should be more closely tailored to the patient requires scientific proof and this is not yet evident. Changing current antibiotic prescribing practices demands a strong microbiology presence, robust antibiotic policies, education and laboratory support, as well as a more careful evaluation of the infected patient and potential pathogen, confirmed or otherwise.206 If there is difficulty in convincing colleagues of the clinical and long-term benefits of decreasing cephalosporin use, then the funders of healthcare may offer a view. Aside from the cost benefits of reducing the amount of these drugs purchased, there are substantial savings to be made from lower numbers of patients who require treatment for the consequences of overgrowth resulting from cephalosporin therapy.81,207 It has been suggested that the clinical freedom enjoyed by the medical profession to prescribe what they like, when they like, should be reviewed for the prescription of antimicrobials.208 Even experienced practitioners may not realize that giving a patient antibiotics affects not just that patient, but also their environment, and all the other people that come into contact with that environment.204,209,210 Removing the right to prescribe antimicrobials freely would divide the medical profession and place a monumental burden upon microbiology and infectious disease specialists. There may also be repercussions for dentists and nurse prescribers. Even if this policy was implemented, inadequate infection control and antibiotic practices elsewhere in the world would erode any progress made in halting the increase of multiply-resistant organisms. The World Health Organization (WHO) must take some responsibility in promoting international discussion on antimicrobial use throughout the world. A multifaceted approach to the control of multiply-resistant organisms is required.202 There are a variety of strategies, some of which have already been mentioned, i.e. antibiotic policies, judicious use of antimicrobials by clinicians, laboratory support, WHO involvement and a strengthening of the role of microbiologists and infectious diseases physicians. Education for everyone is vitally important and in particular, perhaps, for medical students, for whom microbiology teaching should be re-prioritized within the undergraduate curriculum.211 Pharmacists play an important role in restricting over-the-counter sales and in the advice they offer. In the hospitals, they audit prescribing, evaluate adherence to policies and formulary and issue advice on iv-to-oral and antibiotic-stop mechanisms. The microbiology laboratory cannot provide instant identification of all microorganisms, but there are an increasing number of rapid diagnostic techniques available and 24 h processing of non-urgent specimens from high-risk patients can be introduced in order to avoid a sample languishing until the next working day. Laboratory computers should provide the data required for multiple audit and surveillance strategies for infection control. Pharmaceutical research, better definitions of infection and the dangers of prolonged prescribing are other potential control issues.202 In defence of the cephalosporin antibiotics, they provide useful activity against a number of common pathogens, and their low toxicity reassures clinicians and obviates the need for serum levels.212 Patients allergic to penicillin sometimes rely upon a cephalosporin as the only agent available to them. They should not be used for routine prophylaxis, however, but have their efficacy preserved with more rational prescribing.22,213,214 There may well be an argument for revising the recommended adult doses of, in particular, the aminothiazolyl cephalosporins. Reduced bactericidal activity leading to the selection phenomena described may relate to inadequate dosing rather than an inherent therapeutic deficit. Tissue penetration and concentration at the site of infection are other factors to consider. It is also pertinent to say that in the absence of cephalosporins, greater use of other antibiotics would have been required. Not only would these have very likely generated their own particular selection strategies, but also some agents would have almost certainly produced considerable toxic effects, far more so than the cephalosporins. It is unlikely, however, that we would have seen the prolific rise of multiply-resistant organisms if the cephalosporins had never been introduced. This is because few of the existing agents offered such broad-spectrum activity, with such low toxicity, and consequently would not have been universally prescribed. A greater range of antibiotics would have been utilized, diffusing the selection potential. It is the popularity of the cephalosporins, perhaps, that has become their downfall. Resistance inevitably follows the introduction of a new antimicrobial. In intensive care units, the original promise offered by cephalosporins as broad-spectrum therapy was almost immediately eroded by the appearance of resistant organisms, and their use was supplanted by the use of quinolones. The legacy of heavy usage of these drugs, however, resulted in the appearance of multiply-resistant Acinetobacter. Now S. maltophilia flourishes, following the introduction of the carbapenems.215 This ominous progression, played out over the past 20 years, can be likened to a worldwide chess game; as one piece is captured, another moves to threaten.216 If we therefore shift prescribing choice away from the cephalosporins to another antibiotic class, bacteria will evolve resistance mechanisms to the new group chosen.46 Resistance is the price one pays for having an antibiotic and using it, because nature abhors a vacuum and will fill it up if it can.134 Ultimately, the future therapy of infection may almost certainly depend upon the immunologists, with construction of vaccines against virulence determinants or continued work on the development of cytokine inhibitors.210 The latter are already showing positive benefits for patients in ITU.217,218 In conclusion, the selection pressure created by heavy usage of cephalosporin antibiotics over the last 20 years has generated a plethora of multiply-resistant organisms. The possible links between C. difficile, VRE and MRSA serve as a warning for potentially untreatable infection—with ESBLC providing the Gram-negative equivalent. The risks posed by overuse of cephalosporins remain only speculative, unless specific proof is forthcoming. By then, though, we may be contemplating the post-antibiotic era. 1 *Tel: +44-1389-754121; Fax: +44-1389-603910; E-mail: stephanie.dancer@vol.scot.nhs.uk Thanks are due to Mrs Su Byrne for secretarial services and Dr Shelley Heard for original teaching on antibiotics. References 1 Livermore, D. M. ( 1991 ). Mechanisms of resistance to β-lactam antibiotics. Scandinavian Journal of Infectious Diseases Supplement 78 , 7 –16. 2 Wise, R. (1997). β-Lactams: cephalosporins. In Antibiotics and Chemotherapy, 7th edn, (O'Grady, F., Lambert, P. H., Finch, R. G., Greenwood, D., Eds), pp. 202–55. Churchill Livingstone, New York. 3 Pallares, R., Pujol, M., Pena, C., Ariza, J., Martin, F. & Gudiol, F. ( 1993 ). Cephalosporins as risk factors for nosocomial Enterococcus faecalis bacteraemia. A matched case–control study. Archives of Internal Medicine 153 , 1581 –6. 4 Moellering, R. C. ( 1992 ). Emergence of Enterococcus as a significant pathogen. Clinical Infectious Diseases 14 , 1173 –6. 5 Bamberger, D. M. & Dahl, S. L. ( 1992 ). Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital. Archives of Internal Medicine 152 , 554 –7. 6 Pallares, R., Dick, R., Wenzel, R., Adams, J. R. & Nettleman, M. D. ( 1993 ). Trends in antimicrobial utilization at a tertiary teaching hospital during a 15 year period (1978–1992). Infection Control and Hospital Epidemiology 14 , 376 –82. 7 Nicolle, L. E. ( 1988 ) Prior antimicrobial therapy and resistance of Enterobacter, Citrobacter and Serratia to third generation cephalosporins. Journal of Hospital Infection 11 , 321 –7. 8 Follath, F., Costa, E., Thommen, A., Frei, R., Burdeska, A. & Meyer, J. ( 1987 ). Clinical consequences of development of resistance to third generation cephalosporins. European Journal of Clinical Microbiology 6 , 446 –50. 9 Salacata, A. & Chow, J. W. ( 1993 ). Cephalosporin therapeutics for intensive care infections. New Horizon 1 , 181 –6. 10 Maki, D. G. (1984). Comparison of organisms carried on the hands of hospital (ICV) personnel and non-medical control personnel. In Program and Abstracts of the Twenty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 1984. Abstract 521. American Society for Microbiology, Washington, DC. 11 Powell, M. & Sanderson, P. J. ( 1987 ). Resistant coagulase-negative Staphylococci in hospital patients. Journal of Hospital Infection 9 , 48 –53. 12 Thurn, J. R., Crossley, K. B., Gerdst, A. & Baken, L. ( 1992 ). Dynamics of coagulase-negative staphylococcal colonisation in patients and employers in a surgical intensive care unit. Journal of Hospital Infection 20 , 247 –55. 13 Maki, D. G., Alvarado, C. J., Hassemer, C. A. & Zilz, M. A. ( 1982 ). Relation of the inanimate environment to endemic nosocomial infections. New England Journal of Medicine 307 , 1562 –66. 14 Lyytikainen, O., Vaara, M., Jarviluoma, E., Rosenqvist, K., Tiittanen, L. & Valtonen, V. ( 1996 ). Increased resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12-year period. European Journal of Clinical Microbiology and Infectious Diseases 15 , 133 –8. 15 Mouton, R. P., Hermans, J., Simoons-Smith, A. M., Hoogcamp-Korstanje, J. E. & Van Kungeren, B. ( 1990 ). Correlations between consumption of antibiotics and methicillin-resistance in coagulase-negative staphylococci. Journal of Antimicrobial Chemotherapy 26 , 573 –83. 16 Terpstra, S., Noordhoek, G. T., Voesten, H. G. J., Hendriks, B. & Degener, J. E. ( 1999 ). Rapid emergence of resistant coagulase-negative staphylococci on the skin after antibiotic prophylaxis. Journal of Hospital Infection 43 , 195 –202. 17 Archer, G. L. & Armstrong, B. C. ( 1983 ). Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis. Journal of Infectious Diseases 147 , 642 –9. 18 Kernodle, D. S., Barg, N. L. & Kaiser, A. B. ( 1988 ). Low-level colonization of hospitalised patients with methicillin-resistant coagulase-negative staphylococci and emergence of the organisms during surgical antimicrobial prophylaxis. Antimicrobial Agents and Chemotherapy 32 , 202 –8. 19 Edlund, C. & Nord, C. E. ( 1991 ). A model of bacterial– antimicrobial interactions: the case of oropharyngeal and gastrointestinal microflora. Journal of Chemotherapy 3 , 196 –200. 20 Chin, N. X., Neu, N. M. & Neu, H. C. ( 1990 ). Activity of cephalosporins against coagulase-negative staphylococci. Diagnostic Microbiology and Infectious Disease 13 , 67 –9. 21 Monsen, T., Ronnmark, M., Olofsson, C. & Wistrom, J. ( 1999 ). Antibiotic susceptibility of staphylococci isolated in blood cultures in relation to consumption in hospital wards. Scandinavian Journal of Infectious Diseases 31 , 399 –404. 22 James, P. J., Butcher, I. A., Gardner, E. R. & Hamblen, D. L. ( 1994 ). Methicillin-resistant Staphylococcus epidermidis in infection of hip arthroplasties. Journal of Bone and Joint Surgery 76 , 725 –7. 23 Hamory, B. H., Parisi, J. T. & Hutton, J. P. ( 1987 ). Staphylococcus epidermidis: a significant nosocomial pathogen. Journal of Infection Control 15 , 59 –74. 24 Raad, I., Davis, S., Khan, A., Tarrand, J., Elting, L. & Bodey, G. P. ( 1992 ). Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infection Control and Hospital Epidemiology 13 , 215 –21. 25 Gorbach, S. L. ( 1989 ). The role of cephalosporins in surgical prophylaxis. Journal of Antimicrobial Chemotherapy 23 , Suppl. D, 61 –70. 26 Mini, E., Nobili, S. & Periti, P. ( 1997 ). Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis? Drugs 54 , Suppl. 6, 39 –52. 27 Sanderson, P. J. ( 1998 ). Prophylaxis in orthopaedic implant surgery—should we use a glycopeptide? Journal of Antimicrobial Chemotherapy 41 , 322 –5. 28 Hospital Infection Control Practices Advisory Committee. ( 1995 ). Recommendations for preventing the spread of vancomycin resistance. Infection Control and Hospital Epidemiology 16 , 105 –13. 29 Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T. & Tenover, F. C. ( 1997 ). MRSA clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40 , 135 –46. 30 Leigh, D. A., Walsh, B., Leung, A., Tait, S., Peatey, K. & Hancock, P. ( 1990 ). The effect of cefuroxime axetil on the faecal flora of healthy volunteers. Journal of Antimicrobial Chemotherapy 26 , 261 –8. 31 Paull, A. & Morgan, J. R. ( 1986 ). Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 18 , 635 –9. 32 Edgeworth, J. D., Treacher, D. F. & Eykyn, S. J. ( 1999 ). A 25-year study of nosocomial bacteremia in an adult intensive care unit. Critical Care Medicine 27 , 1421 –8. 33 Jones, R. N. ( 1992 ). The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diagnostic Microbiology and Infectious Diseases 15 , Suppl. 2, 3S –10S. 34 Warren, J. W., Anthony, W. C., Hoopes, J. M. & Muncie, H. L. ( 1982 ). Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients. Journal of the American Medical Association 248 , 454 –8. 35 Khardori, N., Elting, L., Wong, E., Schable, B. & Bodey, G. P. ( 1990 ). Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients. Reviews of Infectious Diseases 12 , 997 –1003. 36 Pedersen, S. S., Koch, C., Hoiby, N. & Rosendal, K. ( 1986 ). An epidemic spread of multi-resistant Pseudomonas aeruginosa in a cystic fibrosis centre. Journal of Antimicrobial Chemotherapy 17 , 505 –16. 37 Denton, M. & Kerr, K. G. ( 1998 ). Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clinical Microbiology Reviews 11 , 57 –80. 38 Nordmann, P. & Guibert, M. ( 1998 ). Extended-spectrum β-lactamases in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 42 , 128 –31. 39 Coronado, V. G., Edwards, J. R., Culver, D. H. & Gaynes, R. P. ( 1995 ). Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. National Nosocomial Infections Surveillance (NNIS) System. Infection Control and Hospital Epidemiology 16 , 71 –5. 40 Grassi, G. G. & Grassi, C. ( 1993 ). Cefepime: overview of activity in vitro and in vivo. Journal of Antimicrobial Chemotherapy 32 , Suppl. B, 87 –94. 41 Edlund, C., Stark, C. & Nord, C. E. ( 1994 ). The relationship between an increase in β-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. Journal of Antimicrobial Chemotherapy 34 , 127 –38. 42 George, R. C. & Uttley, A. H. C. ( 1989 ). Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s. Epidemiology and Infection 103 , 403 –13. 43 Magnussen, C. R. & Cave, J. ( 1988 ). Nosocomial enterococcal infections: association with use of third-generation cephalosporin antibiotics. American Journal of Infection Control 16 , 241 –5. 44 Guggenbichler, J. P., Allerberger F. J. & Dierich, M. ( 1986 ). Influence of cephalosporins III generation with varying biliary excretion on faecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatrie und Padologie 21 , 335 –42. 45 Suppola, J. P., Volin, L., Valtonen, V. V. & Vaara, M. ( 1996 ). Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clinical Infectious Diseases 23 , 694 –7. 46 Gentry, L. O. ( 1991 ). Bacterial resistance. Orthopedic Clinics of North America 22 , 379 –88. 47 van der Waaij, D. ( 1987 ). Colonisation resistance of the digestive tract—mechanism and clinical consequences. Nahrung 31 , 507 –17. 48 de Vries-Hospers, H. G., Tonk, R. H. & van der Waaij, D. ( 1991 ). Effect of intramuscular ceftriaxone on aerobic oral and faecal flora of 11 healthy volunteers. Scandinavian Journal of Infectious Diseases 23 , 625 –33. 49 Manzella, J., Benenson, R., Pellerin, G., Kellogg, J., Bell, T., Robertson, M. & Pope, D. ( 2000 ). Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia. Infection Control and Hospital Epidemiology 21 , 789 –91. 50 van der Waaij, D., Hofstra, H. & Wiegersma, N. ( 1982 ). Effect of beta-lactam antibiotics on the resistance of the digestive tract of mice to colonization. Journal of Infectious Diseases 146 , 417 –22. 51 van der Waaij, D. ( 1985 ). Selective decontamination of the digestive tract with oral aztreonam and temocillin. Reviews of Infectious Diseases 7 , Suppl. 4, S628 –34. 52 Woodford, N., Morrison, D., Johnson, P. & George, R. C. ( 1993 ). Antimicrobial resistance amongst enterococci isolated in the United Kingdom, a reference laboratory perspective. Journal of Antimicrobial Chemotherapy 32 , 344 –6. 53 Uttley, A. H. C., Collins, C. H., Naidoo, J. & George, R. C. ( 1988 ). Vancomycin-resistant enterococci. Lancet i , 57– 8. 54 Riley, T. V. ( 1996 ). Clostridium difficile: a high-cost nosocomial pathogen. Culture 17 , 2 –4. 55 Ambrose, N. S., Johnson, M., Burdon, D. W. & Keighley, M. R. B. ( 1985 ). The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. Journal of Antimicrobial Chemotherapy 15 , 319 –26. 56 de Lalla, F., Privitera, G., Ortisi, G., Rizzardini, G., Santoro, D., Pagano, A. et al. ( 1989 ). Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital. Journal of Antimicrobial Chemotherapy 23 , 623 –31. 57 Impallomeni, M., Galletly, N. P., Wort, J., Starr, J. M. & Rogers, T. R. ( 1995 ). Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. British Medical Journal 311 , 1345 –6. 58 Chachaty, E., Depitre, C., Mario, N., Bourneix, C., Saulnier, P., Corthier, G. et al. ( 1992 ). Presence of Clostridium difficile and antibiotic and beta-lactamase activities in faeces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Antimicrobial Agents and Chemotherapy 36 , 2009 –13. 59 McFarland, L. V., Mulligan, M. E., Kwok, R. Y. & Stamm, N. E. ( 1989 ). Nosocomial acquisition of Clostridium difficile infection. New England Journal of Medicine 320 , 204 –10. 60 Zadik, P. M. & Moore, A. P. ( 1998 ). Antimicrobial association of an outbreak of diarrhoea due to Clostridium difficle. Journal of Hospital Infection 39 , 189 –93. 61 Wilcox, M. H., Cunniffe, J. G., Trundle, C. & Redpath, C. ( 1996 ). Financial burden of hospital-acquired infection. Journal of Hospital Infection 34 , 23 –30. 62 Wilcox, M. H. & Smyth, E. T. M. ( 1998 ). Incidence and impact of Clostridium difficile infection in the UK, 1993–1996. Journal of Hospital Infection 39 , 181 –7. 63 The British Thoracic Society. ( 1993 ). Guidelines for the management of community acquired pneumonia in adults admitted to hospital. British Journal of Hospital Medicine 49 , 346 . 64 Spencer, R. C. ( 1998 ). The role of antimicrobial agents in the etiology of Clostridium difficile-associated disease. Journal of Antimicrobial Chemotherapy 41 , Suppl. C, 21 –7. 65 Wort, S. J. & Rogers, T. R. ( 1998 ). Community-acquired pneumonia in elderly people. British Medical Journal 316 , 1690 . 66 Stone, S. P., Beric, V., Quick, A., Balestrini, A. & Kibbler, C. ( 1998 ). The effect of an enhanced infection-control policy on the incidence of Clostridium difficile infection and methicillin-resistant Staphylococcus aureus colonization in acute elderly medical patients. Age and Ageing 27 , 561 –8. 67 McNulty, C., Logan, M., Donald, I. P., Ennis, D., Taylor, D., Baldwin, R. N. et al. ( 1997 ). Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. Journal of Antimicrobial Chemotherapy 40 , 707 –11. 68 Bross, J., Talbot, G. H., Maislin, G., Hurwitz, S. & Strom, B. L. ( 1989 ). Risk factors for nosocomial candidemia: a case–control study in adults without leukaemia. American Journal of Medicine 87 , 614 –20. 69 Wey, S. B., Mori, M., Pfaller, M. A., Woolson, R. F. & Wenzel, R. P. ( 1989 ). Risk factors for hospital-acquired candidaemia. A matched case–control study. Archives of Internal Medicine 149 , 2349 –53. 70 Kinsman, O. S. & Pitblado, K. ( 1989 ). Candida albicans gastrointestinal colonization and invasion in the mouse: effect of antibacterial dosing, antifungal therapy and immunosuppression. Mycoses 32 , 664 –74. 71 Samonis, G., Dassiou, M. & Anastassiadou, H. ( 1994 ). Antibiotics affecting gastrointestinal colonization of mice by yeasts. Journal of Chemotherapy 6 , 50 –2. 72 Thomakos, N., Maraki, S., Liakakos, T., Macheras, A., Kanakavi, S., Marinis, E. et al. ( 1998 ). Effect of cefamandole, cefuroxime and cefoxitin on yeast fecal flora of surgical patients. Chemotherapy 44 , 324 –7. 73 Gubbins, P. O., McConnell, S. A. & Penzak S. R. ( 1999 ). Current management of funguria. American Journal of Health Systems and Pharmacy 56 , 1929 –35. 74 Nassoura, Z., Ivatury, R. R., Simon, R. J., Jabbour, N. & Stahl, W. M. ( 1993 ). Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy. Journal of Trauma 35 , 290 –5. 75 Wade, J. C. (1993). Epidemiology of Candida infections. In Candidiasis, 2nd edn, (Bodey, G. P., Ed.), pp. 85–107. Raven Press, New York. 76 Pfaller, M. A. ( 1995 ). Epidemiology of candidiasis. Journal of Hospital Infection 30 , Suppl., 329 –38. 77 Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T. et al. ( 1991 ). Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. American Journal of Medicine 91 , Suppl. 3B, 86S –89S. 78 Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E. et al. ( 1999 ). Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagnostic Microbiology and Infectious Disease 33 , 217 –22. 79 Schaberg, D. R., Culver, D. H. & Gaynes, R. P. ( 1991 ). Major trends in the microbial etiology of nosocomial infection. American Journal of Medicine 91 , Suppl. 3B, 72S –75S. 80 Swartz, M.N. ( 1994 ). Hospital-acquired infections: diseases with increasingly limited therapies. Proceedings of the National Academy of Sciences, USA 91 , 2420 –7. 81 Frank, M. O., Batteiger, B. E., Sorensen, S. J., Hartstein, A. I., Carr, J. A., McComb, J. S. et al. ( 1997 ). Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clinical Performance and Quality Health Care 5 , 180 –8. 82 Eggimann, P., Glauser, M. P., Auon, M., Meunier, F. & Cacandra, T. ( 1993 ). Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. Journal of Antimicrobial Chemotherapy 32 , Suppl. B, 151 –63. 83 Gould, I. M. ( 1999 ). A review of the role of antibiotic policies in the control of antibiotic resistance. Journal of Antimicrobial Chemotherapy 43 , 459 –65. 84 Medeiros, A. A. ( 1984 ). Beta-lactamases. British Medical Bulletin 40 , 18 –27. 85 Dancer, S. J., Shears, P. & Platt, D. J. ( 1997 ). Isolation and characterization of coliforms from glacial ice and water in Canada's High Arctic. Journal of Applied Microbiology 82 , 597 –609. 86 Livermore, D. M. ( 1987 ). Clinical significance of beta-lactamase induction and stable depression in Gram-negative rods. European Journal of Clinical Microbiology 6 , 439 –45. 87 Amyes, S. G. B. & Miles, R. S. ( 1998 ). Extended-spectrum β-lactamases: the role of inhibitors in therapy. Journal of Antimicrobial Chemotherapy 42 , 415 –7. 88 Pechere, J. C. ( 1989 ). Emergence of resistance in Gramnegative bacilli during beta-lactam therapy: a challenge for the future. European Journal of Cancer and Clinical Oncology 25 , Suppl. 2, S17 –23. 89 Bedenic, B. ( 1999 ). Molecular and genetic characterization of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae. ISID News 5 , 4 –7. 90 Amyes, S. G. B., Payne, D. J. & du Bois, S. K. ( 1992 ). Plasmid-mediated beta-lactamases responsible for penicillin and cephalosporin resistance. Journal of Medical Microbiology 36 , 6 –9. 91 Jacoby, G. A. ( 1994 ). Genetics of extended-spectrum betalactamases. European Journal of Clinical Microbiology and Infectious Diseases 13 , Suppl. 1, S2 –11. 92 Murray, P. R., Granich, G. G., Krogstad, D. J. & Niles, A. C. ( 1983 ). In-vivo selection of resistance to multiple cephalosporins by Enterobacter cloacae. Journal of Infectious Diseases 147 , 590 . 93 Courcol, R. J., Pinkas, M. & Martin, G. R. ( 1989 ). A seven-year survey of antibiotic susceptibility and its relationship with usage. Journal of Antimicrobial Chemotherapy 23 , 441 –521. 94 Mulgrave, L. ( 1991 ). The changing ecology of hospital bacteria and the selective role of cephalosporins. Epidemiology and Infection 106 , 121 –32. 95 Sanders, W. E. & Sanders, C. C. ( 1988 ). Inducible β-lactamases: clinical and epidemiological implications for use of newer cephalosporins. Reviews of Infectious Diseases 10 , 830 –8. 96 Chow, J., Fine, M. J., Shlaes, D. M., Quinn, J. P., Hooper, D. C., Johnson, M. P. et al. ( 1991 ). Enterobacter bacteremia: clinical feature and emergence of resistance during therapy. Annals of Internal Medicine 115 , 585 –90. 97 Ballow, C. H. & Schentag, J. J. ( 1992 ). Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagnostic Microbiology and Infectious Disease 15 , 37S –42S. 98 Karas, J. A., Pillay, D. G., Muckart, D. & Sturm, A. W. ( 1996 ). Treatment failure due to extended-spectrum β-lactamases. Journal of Antimicrobial Chemotherapy 37 , 203 –4. 99 Koontz, F. P., Jones, R. N. & Wenzel, R. P. (1990). Antibiotic resistance: experience at the University of Iona Hospitals and Clinics. In Emerging Trends in Gram-Negative Resistance: A New Concern for Critical Care Medicine, (Wayne, N. J., Ed.), pp. 16–9. Lederle Laboratories. 100 Rice, L. B., Willey, S. H., Papanicolaou, G. A., Medeiros, A. A., Eliopoulos, G. M., Moellering, R. C. et al. ( 1990 ). Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrobial Agents and Chemotherapy 34 , 2193 –9. 101 Meyer, K. S., Urban, C., Eagan, J. A., Berger, B. J. & Rahal, J. J. ( 1993 ). Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Annals of Internal Medicine 119 , 353 –8. 102 Quinn, J. P. ( 1994 ). Clinical significance of extendedspectrum β-lactamases. European Journal of Clinical Microbiology and Infectious Diseases 13 , Suppl. 1, S39 –42. 103 Decker, M. D. & Schaffner, W. (1992). The relationship between the hospital and the community. In Hospital Infections, (Bennett, J. V. & Brachman, P. S., Eds), pp. 221–30. Little Brown, Boston. 104 Weinstein, R. A. ( 1987 ). Resistant bacteria and infection control in the nursing home and hospital. Bulletin of the New York Academy of Medicine 63 , 337 –44. 105 Appelbaum, P. C. ( 1992 ). Antimicrobial resistance to Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15 , 77 –83. 106 Doern, G. V., Brueggemann, A., Holley, H. P. & Rauch, A. M. ( 1996 ). Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994–1995: results of a thirty-centre national surveillance study. Antimicrobial Agents and Chemotherapy 40 , 1208 –13. 107 Jacobs, M. R., Koornhof, H. J., Robins-Browne, R. M., Stevenson, C. M., Vermaak, Z. A., Freiman, I. et al. ( 1978 ). Emergence of multiply resistant pneumococci. New England Journal of Medicine 299 , 735 –40. 108 Negri, M. C., Morosini, M. I., Loza, E. & Baquero, F. ( 1994 ). In vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant Streptococcus pneumoniae populations. Antimicrobial Agents and Chemotherapy 38 , 122 –5. 109 Goldstein, F. W. ( 1999 ). Penicillin-resistant Streptococcus pneumoniae: selection by β-lactam and non β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 44 , 141 –4. 110 Allen, K. D. & Anson, J. J. ( 1996 ). Prevalence of antibiotic resistance in pneumococci is higher in Merseyside. British Medical Journal 313 , 820 . 111 Nava, J. M., Bella, F., Garau, J., Lite, J., Morera, M.-A., Marti, C. et al. ( 1994 ). Predictive factors for invasive disease due to penicillin resistant Streptococcus pneumoniae: a population based study. Clinical Infectious Diseases 19 , 884 –90. 112 Baquero, F., Martinez-Beltran, J. & Loza, E. ( 1991 ). A review of antibiotic resistant patterns of S. pneumoniae in Europe. Journal of Antimicrobial Chemotherapy 28 , Suppl. C, 31 –8. 113 Coffey, T. J., Dowson, C. G., Daniels, M. & Spratt, B. G. ( 1995 ). Genetics and molecular biology of β-lactam resistant pneumococci. Microbial Drug Resistance 1 , 29 –34. 114 Verhaergen, J. & Verbist, L. ( 1998 ). In-vitro activity of 21 β-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 41 , 381 –5. 115 Perez-Trallero, E., Alkorta, M., Garcia-Arenzana, J. M., Iturzaeta, A. & Gomariz, M. ( 1998 ). In-vitro, in-vivo and ex-vivo studies with oral β-lactams against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 41 , 629 –34. 116 Baquero, F. ( 1996 ). Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on collaborative surveillance study. Journal of Antimicrobial Chemotherapy 38 , Suppl. A, 117 –32. 117 Cohen, R., Navel, M., Grumberg, J., Narcy, P., Boucherat, M., Geslin, P. et al. (1997). Single dose ceftriaxone (CRO) for acute otitis media in areas with high resistance to Streptococcus pneumoniae. In Program and Abstracts of the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract LM-34, p. 370. American Society for Microbiology, Washington, DC. 118 Arnold, K. E., Leggiadro, R. J., Breiman, R. F., Lipman, H. B., Schwartz, B., Appleton, M. A. et al. ( 1996 ). Risk factors for carriage of drug resistant Streptococcus pneumoniae among children in Memphis, Tennessee. Journal of Pediatrics 128 , 757 –64. 119 Ford, K. L., Mason, E. O., Kaplan, S. L., Lamberth, L. B. & Tillman, J. ( 1991 ). Factors associated with middle ear isolates of Streptococcus pneumoniae resistant to penicillin in a children's hospital. Journal of Pediatrics 119 , 941 –4. 120 Tan, T. Q., Mason, E. O. & Kaplan, S. L. ( 1993 ). Penicillin-resistant systemic pneumococcal infections in children: a retrospective case-control study. Pediatrics 92 , 761 –7. 121 Renneberg, J., Niemann, L. L. & Gutschik, E. ( 1997 ). Antimicrobial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents. Journal of Antimicrobial Chemotherapy 39 , 135 –40. 122 Marchese, A., Debbia, E. A., Arvigo, A., Pesce, A. & Schito, G. C. ( 1995 ). Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics. Journal of Antimicrobial Chemotherapy 36 , 833 –7. 123 Halls, G. A. ( 1993 ). The management of infections and antibiotic therapy: a European survey. Journal of Antimicrobial Chemotherapy 31 , 985 –1000. 124 Dabernat, H., Geslin, P., Megraud, F., Begue, P., Boulesteix, J., Dubreuil, C. et al. ( 1998 ). Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. Journal of Antimicrobial Chemotherapy 41 , 253 –8. 125 Sifaoui, F., Kitzis, M. D. & Gutmann, L. ( 1996 ). In vitro selection of one-step mutants of S. pneumoniae resistant to different oral β-lactams antibiotics is associated with alterations of PBP2x. Antimicrobial Agents and Chemotherapy 40 , 152 –6. 126 Bauernfeind, A., Jungwirth, R., Schweighart, S. & Theopold, M. ( 1990 ). Antibakterielle Aktivitat und β-Laktamase – Stabilitat von elf Oralcephalosporinen. Infection 18 , Suppl. 3, S155 –67. 127 Goldsmith, C. E., Moore, J. E. & Murphy, P. G. ( 1996 ). Prevalence of antibiotic resistance in pneumococci is higher in Northern Ireland. British Medical Journal 313 , 820 . 128 Granizo, J. J., Aguilar, L. L., Casal, J., Garcia-Rey, C., Dal-Re, R. & Baquero, F. ( 2000 ). Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolides and β-lactam consumption in Spain (1979–1997). Journal of Antimicrobial Chemotherapy 46 , 767 –73. 129 Arason, V. A., Kristinsson, K. G., Sigurdsson, J. A., Stefansdotir, G., Molstad, S. & Gudmundsson, S. ( 1996 ). Do antimicrobials increase the drainage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. British Medical Journal 813 , 387 –91. 130 Gehanno, P., N'Guyen, L., Derriennic, M., Pichon, F., Goehrs, J. M. & Berche, P. ( 1998 ). Pathogens isolated during treatment failures in otitis. Pediatric Infectious Diseases Journal 17 , 885 –90. 131 House of Lords Select Committee on Science and Technology. (1998). Resistance to Antibiotics and Other Antimicrobial Agents. Stationery Office, London. 132 Anonymous. ( 2000 ). Staphylococcus aureus bacteraemia: England and Wales. CDR Communicable Disease Report Weekly 10 , 143 –4. 133 Jevons, M. P. ( 1961 ). Celbenin-resistant staphylococci. British Medical Journal 1 , 124 –5. 134 Batchelor, F. R. (2000). Post penicillin antibiotics: from acceptance to resistance? In Wellcome Witnesses to Twentieth Century Medicine, 6th edn, (Tansey, E. M. & Reynolds, L. A., Eds), pp. 54. The Wellcome Trust, London. 135 Ayliffe, G. A. J. ( 1997 ). The progressive intercontinental spread of MRSA. Clinical Infectious Diseases 24 , Suppl. 1, S74 –9. 136 Dacre, J., Emmerson, A. M. & Jenner, E. A. ( 1986 ). Gentamicin–methicillin-resistant Staphylococcus aureus: epidemiology and containment of an outbreak. Journal of Hospital Infection 7 , 130 –6. 137 Yamaguchi, K. & Ohno, A. ( 1992 ). Consideration on MRSA infections in relation to modern chemotherapy. Nihon Rinsho 50 , 923 –31. 138 Ubukata, K., Nonoguchi, R., Dong Song, M., Matsuhashi, M. & Konno, M. (1990). Expression and inducibility of methicillin resistance encoded by a mecA gene in staphylococci. In Molecular Biology of the Staphylococci, (Novick, R. P., Ed.), pp. 471–89. VCH Publishers, New York. 139 Fukatsu, K., Saito, H., Matsuda, T., Ikeda, S., Furukawa, S. & Muto, T. ( 1997 ). Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Archives of Surgery 132 , 1320 –5. 140 Casewell, M. W. & Hill, R. L. R. ( 1986 ). The carrier state: methicillin resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 18 , 1 –12. 141 Voss, A., Milatovic, D., Wallrauch-Schwarz, C., Rosdahl, V. T. & Braveny, I. ( 1994 ). Methicillin-resistant Staphylococcus aureus in Europe. European Journal of Clinical Microbiology and Infectious Diseases 13 , 50 –5. 142 Voss, A. ( 1996 ). Staphylococcus aureus. Pan-European antibiotic resistance and infection control. Chemotherapie Journal 5 , 5 –6. 143 Saravolatz, L. D., Pohlod, D. & Arking, L. ( 1982 ). Community acquired MRSA infections: a new source for nosocomial outbreaks. Annals of Internal Medicine 97 , 325 –9. 144 Chambers, H. F. ( 1997 ). Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clinical Microbiology Reviews 10 , 781 –91. 145 Okonogi, K. ( 1990 ). Mechanism of β-lactam-resistance in MRSA. Japanese Journal of Clinical Pathology 38 , 983 –9. 146 Okonogi, K., Noji, Y., Kondo, M., Imada, A. & Yakota, T. ( 1989 ). Emergence of methicillin-resistant clones from cephamycin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 24 , 637 –45. 147 Washio, M. ( 1997 ). Risk factors for methicillin-resistant S. aureus (MRSA) infection in a Japanese elderly care nursing home. Epidemiology and Infection 119 , 285 . 148 Crossley, K., Loesch, D., Landesman, B., Mead, K., Chern, M. & Strate, R. ( 1979 ). An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. Journal of Infectious Diseases 139 , 273 –9. 149 Washio, M., Mizoue, T., Kajioka, T., Yoshimitsu, T., Okayama, M., Hamada, T. et al. ( 1997 ). Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in a Japanese geriatric hospital. Public Health 111 , 187 –90. 150 Peacock, J. E., Marsik, F. J. & Wenzel, R. P. ( 1980 ). Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital. Annals of Internal Medicine 93 , 526 –32. 151 Schentag, J. J., Hyatt, J. M., Carr, J. R., Paladino, J. A., Birmingham, M. C., Zimmer, G. S. et al. ( 1998 ). Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clinical Infectious Diseases 26 , 1204 –14. 152 Kind, A. C., Kestle, D. G., Standiford, H. C., Freeman, P. & Kirby, W. M. M. ( 1968 ). Development of staphylococci crossresistant to cephalexin and methicillin. Antimicrobial Agents and Chemotherapy 8 , 405 –9. 153 Wiedemann, B. ( 1986 ). Selection of β-lactamase producers during cephalosporin and penicillin therapy. Scandinavian Journal of Infectious Diseases 49 , Suppl., 100 –5. 154 Noble, W. C. & Naidoo, J. ( 1978 ). Evolution of antibiotic resistance in Staphylococcus aureus: the role of the skin. British Journal of Dermatology 98 , 481 –9. 155 Forbes, B. A. & Schaberg, D. R. ( 1983 ). Transfer of resistant plasmids from Staphylococcus epidermidis to Staphylococcus aureus: evidence for conjugate exchange of resistance. Journal of Bacteriology 153 , 627 –6. 156 Archer, G. L., Niemeyer, D. M., Thanassi, J. A. & Pucci, M. J. ( 1994 ). Dissemination among staphylococci of DNA sequences associated with methicillin resistance. Antimicrobial Agents and Chemotherapy 38 , 447 –54. 157 Hughes, W. T., Armstrong, D., Bodey, G. & The IDSA Working Group. ( 1990 ). Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 161 , 381 –96. 158 Mannion, P. T., Thom, B. T., Reynolds, C. S. & Strachan, C. J. L. ( 1989 ). The acquisition of antibiotic resistant coagulase-negative staphylococci by aortic graft recipients. Journal of Hospital Infection 14 , 313 –23. 159 Asensio, A., Guerrero, A., Quereda, C., Lizan, M. & Martinez-Ferrer, M. ( 1996 ). Colonization and infection with methicillin- resistant Staphylococcus aureus: associated factors and eradication. Infection Control and Hospital Epidemiology 17 , 20 –8. 160 Hill, D. A., Herford, T. & Parratt, D. ( 1998 ). Antibiotic usage and methicillin-resistant Staphylococci aureus: an analysis of casualty. Journal of Antimicrobial Chemotherapy 42 , 676 –7. 161 Smith, D. W. ( 1999 ). Decreased antimicrobial resistance after changes in antibiotic use. Pharmacotherapy 19 , 129S –132S. 162 Wagenvoort, J. H. T. ( 2000 ). Dutch measures to control MRSA and the expanding European Union. Eurosurveillance 5 , 26 –8. 163 Anonymous. ( 1999 ). Four pediatric deaths from community-acquired MRSA – Minnesota and North Dakota, 1997–1999. MMR Morbidity and Mortality Weekly Report 48 , 707 –10. 164 Acar, J. F., Courvalin, P. & Chabbert, Y. A. ( 1970 ). Methicillin-resistant staphylococcaemia: bacteriological failure of treatment with cephalosporins. Antimicrobial Agents and Chemotherapy 10 , 280 –5. 165 Collins, J. K., Mader, J. T. & Kelly, M. T. ( 1983 ). Resistance of methicillin-resistant Staphylococcus aureus to third-generation cephalosporins. Journal of Infectious Diseases 147 , 591 . 166 Soussy, C. J., Deforges, L., Le Van Thoi, J., Chanal, M., Sirot, D., Acar, J. F. et al. ( 1985 ). In vitro activity of ceftriaxone on hospital bacteria. Results of a multicenter study. Pathologie Biologie 33 , 469 –72. 167 Kernodle, D. S., Classen, D. C., Stratton, D. W. & Kaiser, A. B. ( 1998 ). Association of borderline oxacillin-susceptible strains of Staphylococcus aureus with surgical wound infections. Journal of Clinical Microbiology 36 , 219 –22. 168 Stewart, B., Hall, L., Duke, B. & Ball, D. ( 1997 ). Vancomycin-dependent enterococci: curious phenomenon or serious threat? Journal of Antimicrobial Chemotherapy 40 , 734 –5. 169 Spera, R. V. & Farber, B. F. ( 1994 ). Multi drug resistant Enterococcus faecium. An untreatable nosocomial pathogen. Drug 48 , 678 –88. 170 Bradley, S. J., Wilson, A. L. T., Allen, M. C., Sher, H. A., Goldstone, A. H. & Scott, G. M. ( 1999 ). The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. Journal of Antimicrobial Chemotherapy 43 , 261 –6. 171 Fraise, A. P. ( 1996 ). The treatment and control of vancomycin-resistant enterococci. Journal of Antimicrobial Chemotherapy 38 , 753 –6. 172 Wade, J. J. ( 1995 ). The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents – a preliminary report. Journal of Hospital Infection 30 , Suppl., 483 –93. 173 Chadwick, P. R., Chadwick, C. D. & Oppenheim, B. A. ( 1996 ). Report of a meeting on the epidemiology and control of glycopeptide-resistant enterococci. Journal of Hospital Infection 33 , 83 –92. 174 Van den Bogaard, A. E., Mertens, P., London, N. H. & Stobberingh, E. E. ( 1997 ). High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in The Netherlands: is the addition of antibiotics to animal feeds to blame? Journal of Antimicrobial Chemotherapy 40 , 454 –6. 175 Witte, W. & Klare, I. ( 1995 ). Glycopeptide-resistant Enterococcus faecium outside hospitals: a commentary. Microbial Drug Resistance 1 , 259 –63. 176 Lam, S., Singer, C., Tucci, V., Morthland, V. H., Pfaller, M. A. & Isenverg, H. D. ( 1995 ). The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. American Journal of Infection Control 23 , 170 –80. 177 Watanakunakorn, C. ( 1982 ). Treatment of infections due to methicillin-resistant Staphylococcus aureus. Annals of Internal Medicine 97 , 376 –8. 178 Tedesco, F., Markham, R., Gurwith, M., Christie, D. & Bartlett, J. G. ( 1978 ). Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet ii , 226 –8. 179 Taylor, M. E., Oppenheim, B. A., Chadwick, P. R., Weston, D., Palepou, M. F., Woodford, N. et al. ( 1999 ). Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens. Journal of Hospital Infection 43 , 25 –32. 180 Dukta-Malen, S., Leclerq, R., Coutant, V., Duval, J. & Courvalin, P. ( 1990 ). Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria. Antimicrobial Agents and Chemotherapy 34 , 1875 –9. 181 Kjerulf, A., Pallesen, L. & Westh, H. ( 1996 ). Vancomycin-resistant enterococci at a large university hospital in Denmark. APMIS 104 , 475 –9. 182 Tucci, V., Haran, M. A. & Isenberg, H. D. ( 1997 ). Epidemiology and control of vancomycin-resistant enterococci in an adult and children's hospital. American Journal of Infection Control 25 , 371 –6. 183 Morgan, A. S., Brennan, P. J. & Fishman, N. O. ( 1997 ). Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Annals of Pharmacotherapy 31 , 970 –3. 184 Morris, J. G., Shay, D. K., Hebden, J. N., McCarter, R. J., Perdue, B. E., Jarvis, W. et al. ( 1995 ). Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Annals of Internal Medicine 123 , 250 –9. 185 Wendt, C., Wiesenthal, B., Dietz, E. & Ruden, H. ( 1998 ). Vancomycin-resistant and vancomycin-susceptible enterococci on dry surfaces. Journal of Clinical Microbiology 36 , 3734 –6. 186 Dancer, S. J. ( 1999 ). Mopping up hospital infection. Journal of Hospital Infection 43 , 85 –100. 187 Kawalek, M., Gniadkowski, M. & Hryniewicz, W. ( 2000 ). Outbreak of vancomycin-resistant enterococci in a hospital in Gdansk, Poland, due to horizontal transfer of different Tn1546-like transposon variants and clonal spread of several strains. Journal of Clinical Microbiology 38 , 3317 –22. 188 Rozalska, M., Szewczyk, E. & Piotrowski, A. ( 1993 ). Bacterial flora of the hospital environment: identification, susceptibility to disinfecting agents, antibiotics and chemotherapeutics. Medycyna Doswiadczalna i Mikrobiologia 45 , 373 –8. 189 Noble, W. C. & Virani, Z. ( 1992 ). Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiology Letters 93 , 195 –8. 190 Leclercq, R., Derlot, E., Weber, M., Duval, J. & Courvalin, P. ( 1989 ). Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrobial Agents and Chemotherapy 33 , 10 –5. 191 Boyle-Vavra, S., Daum, R. S., Labischinski, H. & Hiramatsu, K. ( 1998 ). Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. Journal of Antimicrobial Chemotherapy 42 , 199 –209. 192 Hanberger, H., Nilsson, L. E., Nilsson, M. & Maller, R. ( 1991 ). Post-antibiotic effect of β-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. European Journal of Clinical Microbiology and Infectious Diseases 10 , 927 –34. 193 Rolinson, G. N. ( 1998 ). Forty years of β-lactam research. Journal of Antimicrobial Chemotherapy 41 , 589 –603. 194 Rolinson, G. N. ( 1980 ). Effect of β-lactam antibiotics on bacterial cell growth rate. Journal of General Microbiology 120 , 317 –23. 195 Gutmann, l., Vincent, S., Billot-Klein, D., Acar, J. F., Mrena, E. & Williamson, R. ( 1986 ). Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coli by some β-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam). Antimicrobial Agents and Chemotherapy 30 , 906 –12. 196 Gould, I. & Mackenzie, F. M. ( 1997 ). The response of Enterobacteriaceae to β-lactam antibiotics—‘round forms, filaments and the root of all evil’. Journal of Antimicrobial Chemotherapy 40 , 495 –9. 197 Hurley, J. C. ( 1992 ). Antibiotic induced release of endotoxin: a reappraisal. Clinical Infectious Diseases 15 , 840 –54. 198 Dofferhoff, A. S. M., Nijland, J. H., de Vries-Hospers, H. G., Mulder, P. O. M., Weits, J. & Bom, V. J. J. ( 1991 ). Effects of different types and combinations of antimicrobial agents on endotoxin release from Gram-negative bacteria: an in-vitro and in-vivo study. Scandinavian Journal of Infectious Diseases 23 , 745 –54. 199 Geddes, A. M. & Gould, I. M. ( 1993 ). The effects of plasmid-mediated cephalosporinases and endotoxins on septic patients. Serodiagnosis, Immunotherapy, and Infectious Disease 5 , 201 –3. 200 Shenep, J. L., Flynn, P. M., Barrett, F. F., Stidham, G. L. & Westenkirchner, D. F. ( 1988 ). Serial quantitation of endotoxemia and bacteremia during therapy for Gram-negative sepsis. Journal of Infectious Diseases 157 , 565 –8. 201 Periti, P. & Mazzei, T. ( 1999 ). New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. International Journal of Antimicrobial Agents 12 , 97 –105. 202 Finch, R. G. ( 1998 ). Antibiotic resistance. Journal of Antimicrobial Chemotherapy 42 , 125 –8. 203 Ruiz Bremon, A., Ruiz-Tovar, M., Perez Gorricho, B., Diaz de Torres, P. & Lopez Rodriguez, R. ( 2000 ). Non-hospital consumption of antibiotics in Spain: 1987–1997. Journal of Antimicrobial Chemotherapy 45 , 395 –400. 204 McGowan, J. E. ( 1994 ). Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infection Control and Hospital Epidemiology 15 , 478 –83. 205 Shales, D. M., Gerding, D. N., John, J. F., Craig, W. A., Bornstein, D. L., Duncan, R. A. et al. ( 1997 ). Guidelines for the prevention of antimicrobial resistance in hospitals. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance. Infection Control and Hospital Epidemiology 18 , 275 –91. 206 Kolmos, H. J. ( 1999 ). Interaction between the microbiology laboratory and clinician: what the microbiologist can provide. Journal of Hospital Infection, 43 , Suppl., S285 –91. 207 Beam, T. R. ( 1988 ). Recent advances in curtailing costs of antimicrobial agents. The Antimicrobic Newsletter 5 , 17 –21. 208 Gould, I. M. ( 1988 ). Control of antibiotic use in the United Kingdom. Journal of Antimicrobial Chemotherapy 22 , 395 –401. 209 Leistevuo, T., Osterblad, M., Toivonen, P., Kahra, A., Lehtonen, A. & Huovinen, P. ( 1996 ). Colonization of resistant faecal aerobic Gram-negative bacilli among geriatric patients in hospital and the community. Journal of Antimicrobial Chemotherapy 37 , 169 –73. 210 Loefler, I. J. P. ( 1996 ). Microbes, chemotherapy, evolution, and folly. Lancet 348 , 1703 –4. 211 Davey, P., Hudson, S., Ridgway, G. & Reeves, D. ( 1993 ). A survey of undergraduate and continuing medical education and about antimicrobial chemotherapy in the United Kingdom. British Journal of Clinical Pharmacology 36 , 511 –9. 212 Neu, H. C. ( 1990 ). Third generation cephalosporins: safety profiles after 10 years of clinical use. Journal of Clinical Pharmocology 30 , 396 –403. 213 Sanderson, P. J. ( 1993 ). Antimicrobiological prophylaxis in surgery; microbiological factors. Journal of Antimicrobial Chemotherapy 31 , Suppl. B, 1 –9. 214 Livermore, D. ( 2000 ). Epidemiology of antibiotic resistance. Intensive Care Medicine 26 , Suppl. 1, S14 –21. 215 Amyes, S. G. B. & Thomson, C. J. ( 1995 ). Antibiotic resistance in the ICU; the eve of destruction. British Journal of Intensive Care 5 , 263 –7. 216 Desowitz, R. S. (1987). New Guinea Tapeworms and Jewish Grandmothers. W. W. Norton & Co., New York, London. 217 Bernard, G. R., Vincent, J. L., Laterre, P. F., LaRosa, S. P., Dhainaut, J. F., Lopez-Rodriguez, A. et al. ( 2001 ). Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine 344 , 699 –709. 218 Vincent, J. L. ( 2000 ). Afelimomab. International Journal of Clinical Practice 54 , 190 –3. © 2001 The British Society for Antimicrobial Chemotherapy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Antimicrobial Chemotherapy Oxford University Press http://www.deepdyve.com/lp/oxford-university-press/the-problem-with-cephalosporins-UpzlyX4Uht

Loading next page...

References (181)

S. Dancer (1999)
Mopping up hospital infection.
The Journal of hospital infection, 43 2
C. Magnussen, Jackle Cave (1988)
Nosocomial enterococcal infections: association with use of third-generation cephalosporin antibiotics.
American journal of infection control, 16 6
A. Dofferhoff, J. Nijland, Hilly Vries-Hospers, P. Mulder, J. Weits, V. Bom (1991)
Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study.
Scandinavian journal of infectious diseases, 23 6
H. Chambers (1997)
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications
Clinical Microbiology Reviews, 10
J. Peacock, F. Marsik, R. Wenzel (1980)
Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital.
Annals of internal medicine, 93 4
M. Taylor, B. Oppenheim, P. Chadwick, D. Weston, M. Palepou, N. Woodford, M. Bellis (1999)
Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens.
The Journal of hospital infection, 43 1
(1989)
Risk factors for nosocomial candidemia: a case–control study in adults without leukaemia
D. Hill, T. Herford, D. Parratt (1998)
Antibiotic usage and methicillin-resistant Staphylococcus aureus: an analysis of causality.
The Journal of antimicrobial chemotherapy, 42 5
W. Sanders, C. Sanders (1988)
Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins.
Reviews of infectious diseases, 10 4
Pierre Gehanno, Laurence Nguyen, Martine Derriennic, François Pichon, J. Goehrs, Patrick Berche (1998)
Pathogens isolated during treatment failures in otitis.
The Pediatric infectious disease journal, 17 10
J. Verhaegen, L. Verbist (1998)
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy, 41 3
Ronald Jones (1992)
The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens.
Diagnostic microbiology and infectious disease, 15 2 Suppl
(1979)
Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolides and -lactam consumption in Spain
S. Amyes, R. Miles (1998)
Extended-spectrum beta-lactamases: the role of inhibitors in therapy.
The Journal of antimicrobial chemotherapy, 42 4
(1996)
In vitro selection of one-step mutants of S. pneumoniae resistant to different oral -lactams antibiotics is associated with alterations of PBP2x
P. Murray, G. Granich, D. Krogstad, A. Niles (1983)
In vivo selection of resistance to multiple cephalosporins by enterobacter cloacae.
The Journal of infectious diseases, 147 3
H. Dabernat, P. Geslin, F. Mégraud, P. Bégué, J. Boulesteix, C. Dubreuil, F. Roque, A. Trinh, A. Scheimberg (1998)
Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media.
The Journal of antimicrobial chemotherapy, 41 2
A. Kjerulf, L. Pallesen, H. Westh (1996)
Vancomycin‐resistant enterococci at a large university hospital in Denmark
APMIS, 104
J. Mcgowan (1994)
Do Intensive Hospital Antibiotic Control Programs Prevent the Spread of Antibiotic Resistance?
Infection Control & Hospital Epidemiology, 15
(1991)
A review of antibiotic resistant patterns of S. pneumoniae in Europe
R. George, A. Uttley (1989)
Susceptibility of enterococci and epidemiology of enterococcal infections in the 1980s
Epidemiology and Infection, 103
K. Meyer, C. Urban, J. Eagan, Barbara Berger, J. Rahal (1993)
Nosocomial Outbreak of Klebsiella Infection Resistant to Late-Generation Cephalosporins
Annals of Internal Medicine, 119
Eriksen Kr (1961)
["Celbenin"-resistant staphylococci].
Ugeskrift for laeger, 123
I. Gould, F. Mackenzie (1997)
For debate The response of Enterobacteriaceae to -lactam antibiotics —'round forms, filaments and the root of all evil'
I. Gould, F. Mackenzie (1997)
The response of Enterobacteriaceae to beta-lactam antibiotics--'round forms, filaments and the root of all evil'.
The Journal of antimicrobial chemotherapy, 40 4
F. lalla, G. Privitera, G. Ortisi, G. Rizzardini, D. Santoro, A. Pagano, E. Rinaldi, P. Scarpellini (1989)
Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital.
The Journal of antimicrobial chemotherapy, 23 4
G. Halls (1993)
The management of infections and antibiotic therapy: a European survey.
The Journal of antimicrobial chemotherapy, 31 6
J. Manzella, R. Benenson, G. Pellerin, J. Kellogg, T. Bell, M. Robertson, Doris Pope (2000)
Choice of Antibiotic and Risk of Colonization With Vancomycin-Resistant Enterococcus Among Patients Admitted for Treatment of Community-Acquired Pneumonia
Infection Control & Hospital Epidemiology, 21
S. Wort, T. Rogers (1998)
Community acquired pneumonia in elderly people
BMJ, 316
C. Ballow, Jerome Schentag (1992)
Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group.
Diagnostic microbiology and infectious disease, 15 2 Suppl
A. Marchese, E. Debbia, Andrea Arvigo, A. Pesce, G. Schito (1995)
Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics.
The Journal of antimicrobial chemotherapy, 36 5
D. Waaij, H. Hofstra, N. Wiegersma (1982)
Effect of β-Lactam Antibiotics on the Resistance of the Digestive Tract of Mice to Colonization
The Journal of Infectious Diseases, 146
C. Edlund, C. Nord (1991)
A model of bacterial-antimicrobial interactions: the case of oropharyngeal and gastrointestinal microflora.
Journal of chemotherapy, 3 Suppl 1
L. Gordon, Archer, D. Niemeyer, J. Thanassi, M. Pucci (1994)
Dissemination among staphylococci of DNA sequences associated with methicillin resistance
Antimicrobial Agents and Chemotherapy, 38
I. Gould (1999)
A review of the role of antibiotic policies in the control of antibiotic resistance.
The Journal of antimicrobial chemotherapy, 43 4
S. Dutka-Malen, R. Leclercq, V. Coutant, J. Duval, P. Courvalin, Paris Xii (1990)
Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria
Antimicrobial Agents and Chemotherapy, 34
D. Bamberger, Stephen Dahl (1992)
Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital.
Archives of internal medicine, 152 3
D. Leigh, B. Walsh, A. Leung, S. Tait, K. Peatey, P. Hancock (1990)
The effect of cefuroxime axetil on the faecal flora of healthy volunteers.
The Journal of antimicrobial chemotherapy, 26 2
Jerome Schentag, J. Hyatt, J. Carr, J. Paladino, M. Birmingham, G. Zimmer, T. Cumbo (1998)
Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 26 5
Fernando Baquero (1996)
Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study.
The Journal of antimicrobial chemotherapy, 38 Suppl A
D. Maki, C. Alvarado, C. Hassemer, M. Zilz (1982)
Relation of the inanimate hospital environment to endemic nosocomial infection.
The New England journal of medicine, 307 25
G. Doern, A. Brueggemann, H. Holley, A. Rauch (1996)
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study
Antimicrobial Agents and Chemotherapy, 40
A. Uttley, C. Collins, Jay Naidoo, R. George (1988)
VANCOMYCIN-RESISTANT ENTEROCOCCI
The Lancet, 331
S. Gorbach (1989)
The role of cephalosporins in surgical prophylaxis.
The Journal of antimicrobial chemotherapy, 23 Suppl D
M. Wilcox, E. Smyth (1998)
Incidence and impact of Clostridium difficile infection in the UK, 1993-1996.
The Journal of hospital infection, 39 3
R. Moellering (1992)
Emergence of Enterococcus as a significant pathogen.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 14 6
Juan Nava, Feliu Bella, Javier Garau, J. Lite, M. Morera, Carme Martí, D. Fontanals, Bernat Font, Valentí Pineda, S. Úriz, F. Deulofeu, Ana Calderón, Pau Durán, Mercè Grau, Antonio Agudo (1994)
Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 19 5
LynneV. McFarland, M. Mulligan, R. Kwok, W. Stamm (1989)
Nosocomial acquisition of Clostridium difficile infection.
The New England journal of medicine, 320 4
J. Wagenvoort (2000)
Dutch measures to control MRSA and the expanding European Union.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 5 3
M. Negri, M. Morosini, E. Loza, F. Baquero (1994)
In vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant Streptococcus pneumoniae populations
Antimicrobial Agents and Chemotherapy, 38
P. Mannion, B. Thom, C. Reynolds, C. Strachan (1989)
The acquisition of antibiotic resistant coagulase-negative staphylococci by aortic graft recipients.
The Journal of hospital infection, 14 4
H. Kolmos (1999)
Interaction between the microbiology laboratory and clinician: what the microbiologist can provide.
The Journal of hospital infection, 43 Suppl
Sayed Ali, Eric Peterson, S. Geraci, P. Pfau, Huy Tran, Bosede Afolabi, Howard Bush, G. Novaro, Hyon Choi, Steven Reis, Timothy Ryan, James Sloand, Paul Winters, J. Corsetti, Georg Dewald, C. Ruff, S. Wiviott, David Morrow, Satishkumar Mohanavelu, S. Murphy, E. Antman, J. Eckfeldt, M. Naunton, J. Brouwers, M. Duyvendak, A. Kolpakchi, Matthew Walters (2002)
The American Journal of Medicine
Juhana Suppola, L. Volin, V. Valtonen, M. Vaara (1996)
Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 23 4
W. Noble, J. Naidoo (1978)
Evolution of antibiotic resistance in Staphylococcus aureus: the role of the skin
British Journal of Dermatology, 98
(1990)
Antibiotic resistance: experience at the University of Iona Hospitals and Clinics. In Emerging Trends in Gram-Negative Resistance: A New Concern for Critical Care Medicine
D. Shlaes, D. Gerding, J. John, W. Craig, D. Bornstein, R. Duncan, M. Eckman, W. Farrer, W. Greene, V. Lorian, S. Levy, J. Mcgowan, S. Paul, J. Ruskin, F. Tenover, C. Watanakunakorn
Infection Control and Hospital Epidemiology Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals Shea Position Paper Infection Co
S. Bradley, Angela Wilson, Michael Allen, Hilary Sher, A. Goldstone, G. Scott (1999)
The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage.
The Journal of antimicrobial chemotherapy, 43 2
Michael Pfaller (1995)
Epidemiology of candidiasis.
The Journal of hospital infection, 30 Suppl
James Hurley (1992)
Antibiotic-induced release of endotoxin: a reappraisal.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 15 5
P. James, Ian Butcher, Eric Gardner, D. Hamblen (1994)
Methicillin-resistant Staphylococcus epidermidis in infection of hip arthroplasties.
The Journal of bone and joint surgery. British volume, 76 5
G. Archer, B. Armstrong (1983)
Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis.
The Journal of infectious diseases, 147 4
D. Livermore (1991)
Mechanisms of resistance to β-lactam antibiotics
Scandinavian Journal of Infectious Diseases
R. Pallarés, R. Dick, R. Wenzel, J. Adams, M. Nettleman (1993)
Trends in Antimicrobial Utilization at a Tertiary Teaching Hospital During a 15-Year Period (1978–1992)
Infection Control & Hospital Epidemiology, 14
Treatment failure due to extended-spectrum -lactamases
Giuliana Grassi, Carlo Grassi (1993)
Cefepime: overview of activity in vitro and in vivo.
The Journal of antimicrobial chemotherapy, 32 Suppl B
A. Salacata, J. Chow (1993)
Cephalosporin therapeutics for intensive care infections.
New horizons, 1 2
P. Periti, T. Mazzei (1999)
New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock.
International journal of antimicrobial agents, 12 2
V. Coronado, J. Edwards, D. Culver, R. Gaynes (1995)
Ciprofloxacin Resistance Among Nosocomial Pseudomonas aeruginosa and staphylococcus aureus in the United States
Infection Control & Hospital Epidemiology, 16
David Smith (1999)
Decreased Antimicrobial Resistance after Changes in Antibiotic Use
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 19
(1991)
Enterobacter bacteremia: clinical feature and emergence of resistance during therapy
P. Nordmann, M. Guibert (1998)
Extended-spectrum beta-lactamases in Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy, 42 2
R. Weinstein (1987)
Resistant bacteria and infection control in the nursing home and hospital.
Bulletin of the New York Academy of Medicine, 63 3
Á. Asensio, A. Guerrero, C. Quereda, Maxima Lizán, Manuel Martínez-Ferrer (1996)
Colonization and Infection With Methicillin-Resistant Staphylococcus aureus: Associated Factors and Eradication
Infection Control & Hospital Epidemiology, 17
N. Chin, N. Neu, H. Neu (1990)
Activity of cephalosporins against coagulase-negative staphylococci.
Diagnostic microbiology and infectious disease, 13 1
J. Dacre, A. Emmerson, E. Jenner (1986)
Gentamicin-methicillin-resistant Staphylococcus aureus: epidemiology and containment of an outbreak.
The Journal of hospital infection, 7 2
(1992)
The relationship between the hospital and the community
C. Edlund, C. Stark, C. Nord (1994)
The relationship between an increase in beta-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances.
The Journal of antimicrobial chemotherapy, 34 1
B. Stewart, L. Hall, B. Duke, D. Ball (1997)
Vancomycin-dependent enterococci: curious phenomenon or serious threat?
The Journal of antimicrobial chemotherapy, 40 5
S. Dancer, P. Shears, D. Platt (1997)
Isolation and characterization of coliforms from glacial ice and water in Canada's High Arctic
Journal of Applied Microbiology, 82
K. Arnold, R. Leggiadro, R. Breiman, H. Lipman, B. Schwartz, Melissa Appleton, K. Cleveland, Herbert Szeto, B. Hill, F. Tenover, J. Elliott, R. Facklam (1996)
Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee.
The Journal of pediatrics, 128 6
H. Vries-Hospers, R. Tonk, D. Waaij (1991)
Effect of intramuscular ceftriaxone on aerobic oral and faecal flora of 11 healthy volunteers.
Scandinavian journal of infectious diseases, 23 5
S. Lam, C. Singer, V. Tucci, V. Morthland, M. Pfaller, H. Isenberg (1995)
The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study.
American journal of infection control, 23 3
F. Tedesco, M. Gurwith, R. Markham, D. Christie, J. Bartlett (1978)
ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS
The Lancet, 312
M. Impallomeni, N. Galletly, S. Wort, J. Starr, T. Rogers (1995)
Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime
BMJ, 311
M. Casewell, R. Hill (1986)
The carrier state: methicillin-resistant Staphylococcus aureus.
The Journal of antimicrobial chemotherapy, 18 Suppl A
Effect of P-Lactam Antibiotics on Bacterial Cell Growth Rate
W. Noble, Zarina Virani, R. Cree (1992)
Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.
FEMS microbiology letters, 72 2
B. Hamory, J. Parisi, J. Hutton (1987)
Staphylococcus epidermidis: a significant nosocomial pathogen.
American journal of infection control, 15 2
M. Różalska, E. Szewczyk, A. Piotrowski (1993)
[Bacterial flora of the hospital environment: identification, susceptibility to disinfecting agents, antibiotics and chemotherapeutics].
Medycyna doswiadczalna i mikrobiologia, 45 3
J. Renneberg, L. Niemann, E. Gutschik (1997)
Antimicrobial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents.
The Journal of antimicrobial chemotherapy, 39 2
L. Mulgrave (1991)
The changing ecology of hospital bacteria and the selective role of cephalosporins
Epidemiology and Infection, 106
P. Sanderson (1993)
Antimicrobial prophylaxis in surgery: microbiological factors.
The Journal of antimicrobial chemotherapy, 31 Suppl B
D. Schaberg, D. Culver, R. Gaynes (1991)
Major trends in the microbial etiology of nosocomial infection.
The American journal of medicine, 91 3B
J. Wade (1995)
The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents--a preliminary report.
The Journal of hospital infection, 30 Suppl
J. Morris, D. Shay, J. Hebden, R. McCarter, B. Perdue, W. Jarvis, Judith Johnson, Thomas Dowling, L. Polish, R. Schwalbe (1995)
Enterococci Resistant to Multiple Antimicrobial Agents, Including Vancomycin: Establishment of Endemicity in a University Medical Center
Annals of Internal Medicine, 123
R. Mouton, J. Hermans, A. Simoons-Smit, J. Hoogkamp-Korstanje, J. Degener, B. Klingeren (1990)
Correlations between consumption of antibiotics and methicillin resistance in coagulase negative staphylococci.
The Journal of antimicrobial chemotherapy, 26 4
C. Soussy, L. Deforges, J. Thoi, M. Chanal, D. Sirot, J. Acar, M. Kitzis, A. Thabaut, M. Meyran, H. Dabernat (1985)
[In vitro activity of ceftriaxone on hospital bacteria. Results of a multicenter study].
Pathologie-biologie, 33 5 Pt 2
(1997)
GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
A. Bogaard, P. Mertens, N. London, E. Stobberingh (1997)
High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in The Netherlands: is the addition of antibiotics to animal feeds to blame?
The Journal of antimicrobial chemotherapy, 40 3
T. Leistevuo, M. Osterblad, P. Toivonen, A. Kahra, A. Lehtonen, P. Huovinen (1996)
Colonization of resistant faecal aerobic gram-negative bacilli among geriatric patients in hospital and the community.
The Journal of antimicrobial chemotherapy, 37 1
(1989)
Risk factors for hospital-acquired candidaemia. A matched case–control study
Kinsman Os, K. Pitblado (1989)
Candida albicans Gastrointestinal Colonization and Invasion in the Mouse: Effect of Antibacterial Dosing, Antifungal Therapy and Immunosuppression Die gastrointestinale Candida albicans‐Besiedlung und ‐Invasion der Maus: Einflulß der antibakteriellen Dosierung, der antimyzetischen Therapie und der I
Mycoses, 32
(1997)
Four pediatric deaths from communityacquired
(2000)
Afelimomab. International Journal of Clinical Practice
J. Edgeworth, D. Treacher, S. Eykyn (1999)
A 25-year study of nosocomial bacteremia in an adult intensive care unit.
Critical care medicine, 27 8
R. Courcol, M. Pinkas, G. Martin (1989)
A seven year survey of antibiotic susceptibility and its relationship with usage.
The Journal of antimicrobial chemotherapy, 23 3
D. Kernodle, N. Barg, A Kaiser (1988)
Low-level colonization of hospitalized patients with methicillin-resistant coagulase-negative staphylococci and emergence of the organisms during surgical antimicrobial prophylaxis
Antimicrobial Agents and Chemotherapy, 32
J. Warren, W. Anthony, J. Hoopes, H. Muncie (1982)
Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients.
JAMA, 248 4
E. Perez-trallero, M. Alkorta, J. García-Arenzana, A. Iturzaeta, M. Gomáriz (1998)
In-vitro, in-vivo and ex-vivo studies with oral beta-lactams against Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy, 41 6
S. Natsch, M. Kasteren, B. Kullberg, J. Meer (1998)
Guidelines for the prevention of antimicrobial resistance in hospitals.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 26 6
I. Loefler (1996)
Microbes, chemotherapy, evolution, and folly
The Lancet, 348
A. Paull, J. Morgan (1986)
Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients.
The Journal of antimicrobial chemotherapy, 18 5
P. Eggimann, M. Glauser, M. Aoun, F. Meunier, T. Calandra (1993)
Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients.
The Journal of antimicrobial chemotherapy, 32 Suppl B
Acar Jf, P. Courvalin, Chabbert Ya (1970)
Methicillin-resistant staphylococcemia: bacteriological failure of treatment with cephalosporins.
Antimicrobial agents and chemotherapy, 10
Sheldon Stone, Virka Beric, A. Quick, Anita Balestrini, C. Kibbler (1998)
The effect of an enhanced infection-control policy on the incidence of Clostridium difficile infection and methicillin-resistant Staphyloccocus aureus colonization in acute elderly medical patients.
Age and ageing, 27 5
I. Loudon (2002)
Wellcome Witnesses to Twentieth Century Medicine
BMJ : British Medical Journal, 325
A. Fraise (1996)
The treatment and control of vancomycin resistant enterococci.
The Journal of antimicrobial chemotherapy, 38 5
S. Terpstra, G. Noordhoek, H. Voesten, B. Hendriks, J. Degener (1999)
Rapid emergence of resistant coagulase-negative staphylococci on the skin after antibiotic prophylaxis.
The Journal of hospital infection, 43 3
P. Chadwick, C. Chadwick, B. Oppenheim (1996)
Report of a meeting on the epidemiology and control of glycopeptide-resistant enterococci.
The Journal of hospital infection, 33 2
Kenji Okonogi, Y. Noji, Masahiro Kondo, Akira Imada, Takeshi Yokota (1989)
Emergence of methicillin-resistant clones from cephamycin-resistant Staphylococcus aureus.
The Journal of antimicrobial chemotherapy, 24 5
N. Ambrose, M. Johnson, D. Burdon, M. Keighley (1985)
The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile.
The Journal of antimicrobial chemotherapy, 15 3
C. Watanakunakorn (1982)
Treatment of infections due to methicillin-resistant Staphylococcus aureus.
Annals of internal medicine, 97 3
D. Livermore (2000)
Epidemiology of antibiotic resistance
Intensive Care Medicine, 26
M. Gilchrist (1995)
Recommendations for Preventing the Spread of Vancomycin Resistance
Infection Control & Hospital Epidemiology, 16
Z. Nassoura, Rao Ivatury, Ronald Simon, Nicholas Jabbour, William Stahl (1992)
Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy.
The Journal of trauma, 35 2
C. Wendt, B. Wiesenthal, E. Dietz, H. Rüden (1998)
Survival of Vancomycin-Resistant and Vancomycin-Susceptible Enterococci on Dry Surfaces
Journal of Clinical Microbiology, 36
Amy Morgan, P. Brennan, N. Fishman (1997)
Impact of a Vancomycin Restriction Policy on Use and Cost of Vancomycin and Incidence of Vancomycin-Resistant Enterococcus
Annals of Pharmacotherapy, 31
F. Goldstein (1999)
Penicillin-resistant Streptococcus pneumoniae: selection by both β-lactam and non-β-lactam antibiotics
Journal of Antimicrobial Chemotherapy, 44
Banerjee Sn, Emori Tg, David Culver, R. Gaynes, W. Jarvis, T. Horan, Edwards, James Tolson, T. Henderson, W. Martone (1991)
Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.
The American journal of medicine, 91 3B
W. Witte, I. Klare (1995)
Glycopeptide-resistant Enterococcus faecium outside Hospitals: a commentary.
Microbial drug resistance, 1 3
Michael Frank, B. Batteiger, S. Sorensen, A. Hartstein, J. Carr, J. McComb, C. Clark, S. Abel, J. Mikuta, R. Jones (1997)
Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program.
Clinical performance and quality health care, 5 4
M. Jacobs, H. Koornhof, R. Robins-Browne, C. Stevenson, Z. Vermaak, I. Freiman, G. Miller, M. Witcomb, M. Isaäcson, J. Ward, R. Austrian (1978)
Emergence of multiply resistant pneumococci.
The New England journal of medicine, 299 14
H. Neu (1990)
Third Generation Cephalosporins: Safety Profiles After 10 Years of Clinical Use
The Journal of Clinical Pharmacology, 30
S. Pedersen, C. Koch, Niels Heiby, K. Rosendal (1986)
An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.
The Journal of antimicrobial chemotherapy, 17 4
T. Coffey, C. Dowson, M. Daniels, B. Spratt (1995)
Genetics and Molecular Biology of β-Lactam-Resistant Pneumococci
Microbial Drug Resistance, 1
G. Samonis, M. Dassiou, H. Anastassiadou (1994)
Antibiotics affecting gastrointestinal colonization of mice by yeasts.
Journal of chemotherapy, 6 1
I. Raad, S. Davis, Asma Khan, J. Tarrand, L. Elting, G. Bodey (1992)
Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia.
Infection Control and Hospital Epidemiology, 13
Péchère Jc (1989)
Emergence of resistance in gram-negative bacilli during beta-lactam therapy: a challenge for the future.
European Journal of Cancer and Clinical Oncology, 25
J. Collins, J. Mader, M. Kelly (1983)
Resistance of methicillin-resistant staphylococcus aureus to third-generation cephalosporins.
The Journal of infectious diseases, 147 3
G. Rolinson (1998)
Forty years of beta-lactam research.
The Journal of antimicrobial chemotherapy, 41 6
A. Geddes, I. Gould (1993)
The effects of plasmid-mediated cephalosporinases and endotoxins on septic patients
Serodiagnosis and Immunotherapy in Infectious Disease, 5
T. Tan, E. Mason, S. Kaplan (1993)
Penicillin-resistant systemic pneumococcal infections in children: a retrospective case-control study.
Pediatrics, 92 6
Swartz Mn (1994)
Hospital-acquired infections: diseases with increasingly limited therapies.
Proceedings of the National Academy of Sciences of the United States of America, 91 7
J. Shenep, P. Flynn, F. Barrett, G. Stidham, David Westenkirchner (1988)
Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis.
The Journal of infectious diseases, 157 3
E. Chachaty, C. Depitre, N. Mario, C. Bourneix, Patrick Saulnier, G. Corthier, Antoine Andremont (1992)
Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo
Antimicrobial Agents and Chemotherapy, 36
K. Crossley, D. Loesch, Barbara Landesman, K. Mead, Myra Chern, R. Strate (1979)
An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. II. Epidemiologic studies.
The Journal of infectious diseases, 139 3
D. Kernodle, D. Classen, C. Stratton, A. Kaiser (1998)
Association of Borderline Oxacillin-Susceptible Strains of Staphylococcus aureus with Surgical Wound Infections
Journal of Clinical Microbiology, 36
(1994)
Multi drug resistant Enterococcus faecium. An untreatable nosocomial pathogen
P. Davey, S. Hudson, G. Ridgway, D. Reeves (1993)
A survey of undergraduate and continuing medical education about antimicrobial chemotherapy in the United Kingdom. British Society of Antimicrobial Chemotherapy Working Party on Antimicrobial Use.
British journal of clinical pharmacology, 36 6
I. Gould (1988)
Control of antibiotic use in the United Kingdom.
The Journal of antimicrobial chemotherapy, 22 4
P. Appelbaum (1992)
Antimicrobial resistance in Streptococcus pneumoniae: an overview.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 15 1
L. Nicolle (1988)
Prior antimicrobial therapy and resistance of Enterobacter Citrobacter and Serratia to third generation cephalosporins.
The Journal of hospital infection, 11 4
C. McNulty, M. Logan, I. Donald, Debbie Ennis, D. Taylor, R. Baldwin, M. Bannerjee, K. Cartwright (1997)
Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy.
The Journal of antimicrobial chemotherapy, 40 5
K. Fukatsu, H. Saito, T. Matsuda, S. Ikeda, S. Furukawa, T. Muto (1997)
Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection.
Archives of surgery, 132 12
M. Pfaller, S. Messer, R. Hollis, R.N Jones, G. Doern, M.E Brandt, R.A Hajjeh (1999)
Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States.
Diagnostic microbiology and infectious disease, 33 4
M. Denton, K. Kerr (1998)
Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia
Clinical Microbiology Reviews, 11
L. Gutmann, S. Vincent, D. Billot-Klein, J. Acar, E. Mrena, R. Williamson (1986)
Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coli by some beta-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam)
Antimicrobial Agents and Chemotherapy, 30
V. Tucci, M. Haran, H. Isenberg (1997)
Epidemiology and control of vancomycin-resistant enterococci in an adult and children's hospital.
American journal of infection control, 25 5
R. Cohen, M. Navel, J. Grumberg, P. Narcy, M. Boucherat, P. Geslin, M. Derriennic, F. Pichon, J. Goehrs (1997)
Single dose ceftriaxone for acute otitis media in area with high resistance to Streptococcus pneumoniae
, 37
G. Rolinson (1980)
Effect of beta-lactam antibiotics on bacterial cell growth rate.
Journal of general microbiology, 120 2
Ean, L, Ouis, Incent, Ay, S. S., Teingrub, Effrey, H. D., Elterbrand (2001)
Efficacy and safety of recombinant human activated protein C for severe sepsis.
The New England journal of medicine, 344 10
Masakazu Washio, Tetsuya Mizoue, Tomoko Kajioka, Takahiro Yoshimitsu, M. Okayama, T. Hamada, Takesumi Yoshimura, Masatoshi Fujishima (1997)
Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in a Japanese geriatric hospital.
Public health, 111 3
J. Guggenbichler, F. Allerberger, M. Dierich (1986)
Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy.
Padiatrie und Padologie, 21 4
N. Woodford, D. Morrison, A. Johnson, R. George (1993)
Antimicrobial resistance amongst enterococci isolated in the United Kingdom: a reference laboratory perspective.
The Journal of antimicrobial chemotherapy, 32 2
H. Hanaki, K. Kuwahara-Arai, S. Boyle‐Vavra, R. Daum, H. Labischinski, K. Hiramatsu (1998)
Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.
The Journal of antimicrobial chemotherapy, 42 2
K. Ford, E. Mason, S. Kaplan, L. Lamberth, J. Tillman (1991)
Factors associated with middle ear isolates of Streptococcus pneumoniae resistant to penicillin in a children's hospital.
The Journal of pediatrics, 119 6
R. Knox (1960)
“Celbenin”-resistant Staphylococci
British Medical Journal, 2
L. Rice, S. Willey, G. Papanicolaou, A. Medeiros, G. Eliopoulos, R. Moellering, G. Jacoby (1990)
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility
Antimicrobial Agents and Chemotherapy, 34
N. Thomakos, S. Maraki, Theodore Liakakos, Anastasios Macheras, S. Kanavaki, E. Marinis, M. Sehas, A. Margioris, George Samonis (1998)
Effect of Cefamandole, Cefuroxime and Cefoxitin on Yeast Fecal Flora of Surgical Patients
Chemotherapy, 44
(1995)
Antibiotic resistance in the ICU; the eve of destruction
M. Kawalec, M. Gniadkowski, W. Hryniewicz (2000)
Outbreak of Vancomycin-Resistant Enterococci in a Hospital in Gdańsk, Poland, due to Horizontal Transfer of Different Tn1546-Like Transposon Variants and Clonal Spread of Several Strains
Journal of Clinical Microbiology, 38
P. Zadik, A. Moore (1998)
Antimicrobial associations of an outbreak of diarrhoea due to Clostridium difficile.
The Journal of hospital infection, 39 3
D. Waaij (1985)
Selective Decontamination of the Digestive Tract with Oral Aztreonam and Temocillin
Clinical Infectious Diseases, 7
R. Leclercq, E. Derlot, Markus Weber, J. Duval, P. Courvalin (1989)
Transferable vancomycin and teicoplanin resistance in Enterococcus faecium
Antimicrobial Agents and Chemotherapy, 33
M. Powell, P. Sanderson (1987)
Resistant coagulase-negative staphylococci in hospital patients.
The Journal of hospital infection, 9 1
R. Spencer (1998)
The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease.
The Journal of antimicrobial chemotherapy, 41 Suppl C
V. Arason, K. Kristinsson, J. Sigurdsson, G. Stefánsdóttir, S. Molstad, S. Gudmundsson (1996)
Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study
BMJ, 313
P. Gubbins, S. McConnell, S. Penzak (1999)
Current management of funguria.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 56 19
The problem with cephalosporins
A. Bremón, M. Ruiz-Tovar, B. Gorricho, P. Torres, R. Rodríguez (2000)
Non-hospital consumption of antibiotics in Spain: 1987-1997.
The Journal of antimicrobial chemotherapy, 45 3

Publisher: Oxford University Press
Copyright: © 2001 The British Society for Antimicrobial Chemotherapy
ISSN: 0305-7453
eISSN: 1460-2091
DOI: 10.1093/jac/48.4.463
Publisher site: See Article on Publisher Site

Abstract

Abstract The cephalosporin antibiotics have become a major part of the antibiotic formulary for hospitals in affluent countries. They are prescribed for a wide variety of infections every day. Their undoubted popularity relies upon lesser allergenic and toxicity risks as well as a broad spectrum of activity. It is the latter feature, however, that encourages the selection of microorganisms that are resistant to these agents. There are long-term implications for the treatment and control of this heterogeneous group of superinfections. When clinicians evaluate a septic patient, it is understandable that they choose empirical therapy with a cephalosporin whilst awaiting microbiology and other tests, since bacterial identification and antimicrobial testing still usually require 24–48 h. The broad-spectrum capability of these drugs, however, encourages rapid overgrowth of some microorganisms that are neither eliminated nor inhibited by therapy. These organisms not only have pathogenic potential, they may also be multiply resistant to antibiotics. This review discusses the evidence that cephalosporin usage is the most important factor in the selection and propagation of microorganisms such as Clostridium difficile, methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, multiply resistant coliforms and vancomycin-resistant enterococci, the continuing increase of which threatens the future of antimicrobial therapy. Introduction Although widely accepted as broad-spectrum antibiotics, cephalosporins are not active against all the bacteria commonly isolated in a hospital microbiology laboratory.1 Organisms that are not inhibited by cephalosporin therapy consequently overgrow, with varying potential to cause infection.2,3 Some of these are instantly recognizable as pathogens; others, although originally regarded as commensal or of low risk status, have subsequently been shown to cause disease.4 Furthermore, there is an association between cephalosporin usage and the emergence of multiply-resistant organisms.2,5–9 Microorganisms selected by cephalosporin therapy include commensal organisms such as coagulase-negative staphylococci (CNS), Pseudomonas aeruginosa, enterococci and Candida albicans, and organisms of more established pathogenicity, e.g. Clostridium difficile, penicillin-resistant pneumococci, multiply-resistant coliforms and methicillin-resistant Staphylococcus aureus (MRSA). Some of these organisms are constitutively resistant to cephalosporins while others have acquired resistance, usually as part of a multiple resistance package. This review discusses the evidence for a link between cephalosporins and overgrowth of certain microorganisms, including those that are multiply resistant to antibiotics. Inherently resistant microorganisms Coagulase-negative staphylococci CNS are the most prevalent skin commensals. Hospitals are a source of CNS, which includes carriage by patients and staff,10–12 and a reservoir in the hospital environment.13 There appears to be a relationship between antibiotic usage and antibiotic resistances of CNS in hospitals.14,15 Isolates from patients are generally multiply-resistant due to the continued heavy exposure of the hospital, staff and patients to antibiotics.11,16 Patients newly admitted to hospital tend to acquire hospital CNS within hours of their admission, especially if prescribed antibiotic therapy.11,17,18 Experimental models show that the selective pressure exerted by broad-spectrum cephalosporins brings about a rapid overgrowth of staphylococci that are resistant to the antibiotics used.19 This is also seen clinically, as most antibiotic-resistant hospital CNS are resistant to methicillin and are therefore relatively unaffected by cephalosporins.20 They consequently proliferate upon and within patients receiving these antibiotics.17,18,21 This property is not exclusive to the cephalosporins, as any antibiotic could theoretically have the same effect.15,16 It is very difficult to rank antibiotics, let alone individual β-lactam agents, according to their selective ability, but there have been studies showing that methicillin resistance in CNS is significantly associated with therapeutic and prophylactic use of cephalosporins.15,18,22 Methicillin-resistant CNS encouraged by cephalosporin therapy may have clinical implications for some patients.6,17,18,22 CNS are commonly associated with infections of artificial prostheses, including plastic catheters, and will generate persistent low-grade infections unless the prosthesis is removed.23 Current management usually involves removal of such prostheses under glycopeptide cover, which increases the overall usage of these antibiotics.24 Many hospitals in developed countries consume large amounts of cephalosporin antibiotics, particularly in surgical departments as the preferred choice for prophylaxis.25 This is being questioned at the present time for some specialities, because of concerns about the increasing prevalence of methicillin-resistant staphylococci. Some centres are already advocating a change from first- and second-generation cephalosporins to glycopeptides, but this move may be premature for others.22,26,27 These antibiotics are both expensive and toxic, and their use has been discouraged following the emergence of glycopeptide-resistant enterococci (GRE) and more recently, glycopeptide intermediately resistant S. aureus (GISA).28,29 Oxidative non-fermentative Gram-negative bacilli P. aeruginosa is another common isolate from patients. Ceftazidime and some newer cephalosporins aside, most cephalosporins encourage overgrowth of this organism because it is inherently resistant to these agents.2,30 Consumption of cephalosporin antibiotics in a hospital is associated with an increase in the isolation of P. aeruginosa.31,32 Ceftazidime use itself leads to a significant reduction in susceptibility of P. aeruginosa to this antibiotic.5,9,33 If its use is subsequently restricted, the proportion of susceptible P. aeruginosa increases once again.5 Oral cephalosporins prescribed for urinary tract infections select for P. aeruginosa, which overgrows and may then mask the identity of the original pathogen.34 Repeat swabs consequently incite inappropriate treatment for an organism that is not necessarily the primary pathogen and may only be of low clinical significance. Therapy with second- or third-generation cephalosporins also encourages overgrowth of Stenotrophomonas maltophilia.31,35,36 This organism may require additional treatment, although therapy is difficult because it is often multiply resistant to antibiotics.37 Ceftriaxone or ceftazidime therapy selects resistant mutants from pre-existing susceptible strains of Pseudomonas.31,33,38 In addition, these resistant mutants may be able to secondarily transfer the capacity for extendedspectrum β-lactamases (ESBLs) into Enterobacteriaciae.38 There are few therapeutic options for infections caused by these strains, and the only effective oral agents (quinolones) are losing ground because of increasing resistance.39 Enterococci Enterococci are also associated with cephalosporin therapy.3,19,40–45 These faecal-type streptococci first provoked interest as emerging pathogens in both hospital and community in the 1980s.4 Most infection occurs in the urinary tract, but patients who have received, or are receiving, parenteral cephalosporins appear to be at risk from enterococcal infections in a variety of sites, including blood.3,43,45 This is because enterococci are inherently resistant to cephalosporins and are able to colonize gastrointestinal sites previously populated by cephalosporin-susceptible organisms.19,41,46 This is particularly well illustrated by current theories regarding colonization resistance.47 Prescribing an antibiotic that decreases colonization resistance of the alimentary canal allows increased population densities (overgrowth) of potentially pathogenic bacteria. This correlates with mucosal invasion followed by translocation to lymph nodes. Overgrowth may also be associated with development or acquisition of resistance to the antibiotic prescribed.47 The majority of healthy volunteers given cephalosporins acquire a substantially increased proportion of enterococci in the gastrointestinal tract.30,41,48 This is also seen in patients.44,45,49 Animal studies describe profound effects of cephalosporin agents on colonization resistance, although antibiotics other than cephalosporins are also implicated.50 It is difficult to apportion the effects of different antibiotics on colonization resistance because there are so few detailed studies specifically examining this. Some antibiotics, however, seem to be better able to maintain the status of the indigenous gastrointestinal flora than others.41,51 Patients tend to be more vulnerable than volunteers to changes in colonization resistance and enterococcal overgrowth precedes infection of the urinary tract, wounds, catheter sites and/or blood.3,43,45 As with Pseudomonas, therapeutic options for clinically significant isolates are limited, and management has been further complicated by an increase in resistance to amoxicillin and gentamicin.52 GRE are virtually untreatable,53 and are discussed further below. Clostridium difficile C. difficile has long been associated with a range of clinical diseases, from antibiotic-associated diarrhoea to pseudomembranous colitis. Overgrowth of C. difficile, with or without clinical symptoms, is not exclusively associated with cephalosporins and has been reported following administration of many other antibiotics.54 However, overgrowth occurs more commonly after cephalosporin therapy.19,41,55–57 Healthy volunteers given oral cephalosporins virtually all excrete C. difficile after 10 days of therapy.58 Treatment options for compromised patients usually include oral vancomycin or metronidazole, or both. Treatment failures occur frequently and precipitate the patient into and out of isolation, such is the propensity for spread of this spore-forming anaerobe.59 The organism may also be associated with outbreaks, which are debilitating to patients and costly for the hospital.57,60,61 There has been a substantial increase of C. difficile in the UK over the last decade.62 It is possible that the British Thoracic Society endorsement of cephalosporins as first-line treatment for community-acquired pneumonia has played some part in the increase of this organism.63–65 A recent review states that the association between cephalosporins and C. difficile overgrowth is now so well established that cephalosporins should not be prescribed in care of the elderly units.64 This view has already been successfully transcribed into clinical practice, whereby restriction of cephalosporin use has resulted in a decrease in the numbers of patients with C. difficile.66,67 Candida albicans Overgrowth is not solely a bacterial domain. C. albicans awaits any opportunity afforded by antibacterial therapy, yeast infections often following a course of antibiotics. Antibacterial therapy has consistently been shown to be a major independent risk factor for the development of systemic candidosis.68,69 By no means exclusive to treatment with cephalosporins, Candida overgrows following exposure to most antibiotics.19,30,41 It is those with the broadest spectrum of cover, however, that are more likely to encourage overgrowth.44 Quinolones and aminoglycosides, for example, do not induce candidosis as rapidly or as often as cephalosporins.70,71 When volunteers are given oral cephalosporins, most become colonized by yeasts within 2 or 3 days of starting therapy;30 in another study, a group given amoxicillin did not show any increase in colonization with Candida.19 Patients treated with cefaclor, cefalexin, cefradine, cefuroxime, ceftriaxone, latamoxef or ceftazidime have an increased risk of developing Candida.2,44 Volunteers receiving parenteral ceftriaxone also show an overgrowth of yeasts in faecal flora.48 Surgical patients treated with cephalosporins demonstrate increased colonization with Candida.72 Patients are commonly found to have Candida from a throat swab soon after cefotaxime is initiated. Such patients are also at risk of candiduria, especially if the patient is catheterized.73 Candidaemia may follow if colonization of superficial sites and/or the urine is ignored.68,74 The more sites growing Candida, the higher the risk of invasive candidosis.75 Treating clinically significant candidal overgrowth is difficult, especially when there are so few antifungal agents available. There has been a huge increase in infections due to Candida over the past 20 years76,77 and there is no sign that numbers are abating.78 In hospital patients, the rate of blood-stream infection due to Candida spp. increased by almost 500% during the 1980s.76,77 Whilst there may be several different reasons for this, including greater awareness, more clinical interventions and better laboratory techniques, the increasing amount of Candida mirrors the increasing use of cephalosporins introduced over this period. Recent trends in the aetiology of hospital-acquired infections There has been a major shift in the aetiology of hospital-acquired infections during the 1980s in contrast to the 1970s, that is, an increase in the laboratory isolation of CNS, Candida, S. aureus, enterococci, P. aeruginosa and Enterobacter between 1980 and 1986–1989.77,79 Taken as a whole, the shifts are away from more easily treated pathogens towards more resistant pathogens with fewer options for therapy.79,80 With the complexity and choice of antibiotic therapy nowadays, it is difficult to find specific evidence for the association of commensal overgrowth with the cephalosporin antibiotics alone. One study looked at hospital-acquired bacteraemia in an adult intensive care unit over 25 years (1971–1995).32 Here, the use of amoxicillin plus gentamicin was gradually replaced by cephalosporins as first-line choice for the treatment of bacteraemic patients. During the last 5 years of the study, the number of bacteraemias increased two-fold, largely owing to increased isolation of enterococci, CNS, intrinsically antibiotic-resistant Gram-negative organisms (particularly P. aeruginosa) and Candida. Whilst the cephalosporins were introduced in the early 1980s, their prescribing frequency did not equal that of gentamicin until the 1990s. The organisms highlighted are the same as those already mentioned as being associated with cephalosporin therapy. The authors attributed the change in the spectrum of organisms to the changes in antibiotics used over the time period studied.32 An additional study shows that if cephalosporin usage is reduced as part of an overall reduction in antimicrobial prescribing, there is a decrease in hospital-acquired infections, namely, enterococcal and selected Gram-negative bacteraemias, and MRSA and S. maltophilia colonization or infection.81 Others have documented the association of cephalosporins with staphylococci, enterococci, multiply-resistant Gram-negative bacilli, yeasts and C. difficile.2,82,83 The next section describes a group of multiply-resistant bacteria rapidly increasing in hospitals throughout the world. It appears that cephalosporin usage selects for and encourages propagation of these organisms. It is even possible that the cephalosporin antibiotics play a role in the molecular initiation of resistance for some. Microorganisms with acquired resistance Extended-spectrum β-lactamase-producing coliforms β-Lactamases are the major determinants of resistance to β-lactam antibiotics.84 All Gram-negative bacteria elaborate chromosomally mediated β-lactamase enzymes. These are typically low level in coliforms isolated from human-free environments but may be induced in a wide variety of species by exposure to β-lactam drugs.85,86 The prevalence of β-lactamases has forced pharmaceutical companies to seek alternative agents that are resistant to β-lactamase attack.87 Cefotaxime and ceftazidime were initially regarded as indestructible from plasmid-mediated β-lactamases, but this belief has since been shattered following a cascade of reports describing plasmid-mediated resistance to both of these drugs.88,89 There are now increasing numbers of plasmid-mediated ESBLs described every year. Almost all of them are derivatives of the well-known TEM and SHV-1 β-lactamases.90 Variants of these inactivate third-generation cephalosporins and monobactams, having arisen by spontaneous mutation and being only marginally different in amino acid sequence from the parent enzymes.1 An additional mechanism of resistance is the capture on plasmids of normally chromosomal genes from Enterobacter cloacae, Citrobacter freundii or P. aeruginosa, which can provide Klebsiella pneumoniae or Escherichia coli with resistance to α-methoxy-β-lactams (cefoxitin and cefotetan) as well as to oxyimino-β-lactams (cefotaxime, ceftriaxone and ceftazidime).91 A resistant organism isolated during therapy to one cephalosporin may thus demonstrate reduced susceptibility to other antibiotics, not necessarily within the same chemical class.92 Multiply-resistant coliforms are associated with high-level usage of cephalosporins, particularly cefotaxime, ceftriaxone and ceftazidime.5–9, 44, 87, 93–97 These antibiotics induce and select for ESBL coliforms (ESBLC).87,95,98 If cephalosporins are avoided, there is less chance of selecting these highly resistant bacteria, and coliform susceptibility rates rise.5,99 At a hospital in New York, multiply-resistant E. cloacae isolates from the intensive care unit increased dramatically between 1988 and 1990.97 As a response, use of ceftazidime was severely restricted in favour of piperacillin in combination with an aminoglycoside. Following this change, susceptibility of E. cloacae isolates to ceftazidime increased from 54% to 75%, whilst the total number of multiply-resistant E. cloacae fell. No other major changes in susceptibility patterns were seen.97 Some resistant coliforms merely colonize patients; others invade to cause infection.8 Yet other epidemic strains spread to cause outbreaks of virtually untreatable disease.100,101 The location of antibiotic resistance mechanisms on plasmids facilitates easy spread between species and genera, and is most likely to occur in the gastrointestinal tract.46,102 Some physicians have already recognized the fact that cephalosporin usage may play a role in the selection of ESBL and therefore prescribe amoxicillin in conjunction with an antibiotic of another class for first-line treatment of community-acquired pneumonias.87 Similarly, some surgeons have reverted to the ‘old-fashioned’ combination of amoxicillin and gentamicin for surgical patients.87 The latter combination is less likely to encourage overgrowth of susceptible enterococci, yeasts and C. difficile, than would occur if a cephalosporin was the antibiotic of choice.3,19,57,72 Hospitals contain a concentrated reservoir of resistant coliforms, but a dilute version exists in the community. The path between the hospital and the community runs both ways.103 Even patients with no prior hospital contact can display clinically significant infection with multiply-resistant coliforms.104 Critically ill patients in intensive care units rapidly acquire such organisms, even if not previously colonized, and a battle often ensues between microbiologist and organism for time to allow the patient to recover from initial pathology before succumbing to hospitalacquired resistant microbes. Penicillin-resistant pneumococci Clinically significant infection with penicillin-resistant pneumococci (PRP) is prevalent worldwide.105 At present, the median MIC for strains in the USA lies between 0.05 and 0.1 mg/L and is continuing to rise. Most infections with intermediately resistant pneumococci (MIC 0.1–1.0 mg/L penicillin) are treatable with increased doses of penicillin, but isolates are now showing high-level resistance (>2.0 mg/L).106 Some of these demonstrate resistance to third-generation cephalosporins, and this proportion is also increasing.106 PRP are associated with extensive prior antimicrobial therapy,107 particularly with β-lactam antibiotics.108–112 They may be selected at the infection site or in the nasopharynx.109 Resistant strains may even reside in the nasopharynx before treatment is initiated and are then encouraged by the antibiotic given. It is also possible that penicillinsusceptible strains are transformed in vivo to strains that have a lower susceptibility to penicillin.113 Any antibiotic in theory has the potential to select resistant strains provided that the local concentration of the drug is high enough to inhibit susceptible cells whilst encouraging a resistant subset.109 The risk of selection is increased if patients are under-dosed or given prolonged courses of antibiotics, or if drugs with inadequate activity against pneumococci are prescribed.114,115 The aminopenicillins have been widely regarded as being disproportionately responsible for selecting PRP, but this may be only because the emergence of this pathogen coincided with increased consumption of these antibiotics.116 It is entirely possible that increased prescribing of other antibiotics, e.g. cephalosporins, macrolides and co-trimoxazole, is equally or more important than aminopenicillins in the promotion of PRP.116–119 Studies examining the effect of antibiotics on the carriage of PRP are often flawed in their design and conclusions.109 Authors do not often calculate the relative selective pressures of different classes of antibiotics;117–119 in many studies, investigators fail even to identify the specific antibiotics given, referring only to the generic term ‘antibiotics’.109 Even more unusually, some authors identify the classes of antibiotics that select resistant strains, but fail to complete the analysis. In one of these studies, co-amoxiclav was shown to be associated with a minimal increase in the incidence of PRP carriage (from 14% to 16%) whilst the use of other unidentified antibiotics was associated with a much greater increase in PRP incidence (from 39% to 70%).120 It is indisputable that aminopenicillins promote the carriage of PRP, because in common with other β-lactams, they select PRP strains already present in the oropharynx. It is also the case that there are other penicillin-resistant streptococci present in the oral cavity, which could serve as reservoirs for resistance genes that lead to alterations in pneumococcal penicillin-binding proteins (PBPs).121 There are some studies that detail a connection between cephalosporins and PRP.2,105,109,122–124 One compares the efficacy of cefixime versus co-amoxiclav in children with acute otitis media.124 Cefixime was associated with a rate of selection of PRP of 41.9%, compared with 15.9% for co-amoxiclav.124 The selection of PRP by oral cephalosporins, both in vitro and in vivo, can be explained by their reduced activities against PRP, as well as by the fact that the modification of a single penicillin-binding protein, PBP 2x, may result in a marked increase in MICs.124–126 Selection by cephalosporins occurs at higher frequencies than that by amoxicillin.125 Even very potent broad-spectrum cephalosporins are capable of selecting PRP.117 In a study whereby a single dose of ceftriaxone was compared with a 10 day course of co-amoxiclav for children with acute otitis media in an area of high PRP prevalence, nearly twice as many PRP were selected by the cephalosporin as by co-amoxiclav (27.4% and 14.5%, respectively).117 Other work indicates that oral cephalosporins promote mutants with higher MICs of parenteral third-generation cephalosporins than of penicillin.105 Oral cephalosporins are often prescribed for streptococcal pharyngitis, where colonizing pneumococci normally reside. Use of these agents may be responsible for the sudden increase in PRP recorded by a community survey in Northern Ireland;127 consumption has certainly been correlated with the prevalence of high-level penicillin resistance in Spain.128 The inference is, therefore, that cephalosporins select for and encourage resistance to β-lactam antibiotics in pneumococci colonizing the oropharynx.109 Furthermore, PRP have greater potential to spread than susceptible strains.129 Concurrent resistance to other antibiotics, including macrolides and co-trimoxazole in multiply-resistant strains, will not only select still greater numbers of resistant populations in the nasopharynx, but may also lead to clinical failures, thereby increasing the risk of dissemination of PRP.130 The pathogenicity of this organism is such that the increasing incidence worldwide is of major concern to clinicians. MRSA The prevalence of MRSA is also giving cause for concern.131S. aureus itself has always been regarded as a pathogen and now there are only a few remaining antibiotics effective against resistant strains. Potential usage of any member of the β-lactam group is excluded once S. aureus becomes resistant to methicillin.1 There is a steady increase of new cases nationally and an increasing proportion of MRSA from total numbers of staphylococcal bacteraemias.132 MRSA was first described in 1961 in Britain, but despite fear of spread, there were only sporadic outbreaks in the 1960s and 1970s.133–135 Cephalosporins were widely introduced in 1980 and the first epidemics of MRSA were reported in London during the middle 1980s.136 By 1990, most parts of the UK were affected. The Japanese experience cites the introduction of second- and third-generation cephalosporins in the early 1980s as playing a significant part in the emergence and spread of MRSA in Tokyo hospitals.137–139 The steady increase of MRSA in Europe, including Britain and Italy, has also been attributed to the use of cephalosporins.40,122,135,140–142 A report from America describes a community outbreak of MRSA among iv drug abusers who self-administered cephalosporins for prophylactic purposes.143 At least three mechanisms account for methicillin resistance in S. aureus: production of PBP 2a or 2′ encoded by the chromosomal mec(A) gene, production of modified PBPs and inactivation of methicillin by β-lactamase.144 There is insufficient evidence to prove the molecular role played by antibiotics in the acquisition of these mechanisms but it is widely believed that antibiotics are asso- ciated with the induction, selection and propagation of MRSA.137,138,140,145–151 The induction hypothesis originates firstly from training procedures, whereby methicillinsusceptible S. aureus (MSSA) is cultured in broth containing sub-MIC levels of β-lactam antibiotics, in particular, cefazolin and ceftizoxime.138 It is possible to create MRSA (MIC > 1000 mg/L) from such experiments, although rather more difficult to transpose them into a clinical context. Methicillin-resistant clones can also be identified from S. aureus specifically resistant to cephamycin antibiotics,146 and serial exposure of S. aureus to cefalexin discs induces the development of staphylococci cross-resistant to cefalexin and methicillin.152 The latter work also showed that once induced, the capacity for methicillin resistance was not easily lost.152 Considering selection, some authors specifically cite cephalosporin therapy as a major factor in the appearance of MRSA.149–151 Once established, continued use of cephalosporins encourages the spread of the organism.137,151 It is reasonable to assume that all members of the β-lactam class of antibiotics have some ability to induce methicillin resistance in staphylococci, albeit difficult to prove.152 It is even more difficult to apportion the ability for the selection process between individual β-lactam agents.15,153 If the capacity for generating MRSA is regarded as similar between β-lactam agents, however, then cephalosporins shoulder much of the responsibility owing to the frequency of their use. There are further issues that may be important in the evolution of MRSA. We may accept that the most plausible hypothesis is repeated exposure of S. aureus to β-lactam antibiotics,152,154 but it is also possible that inadequate doses, or too short a course, of the same agents may fail to eradicate infection with MSSA whilst presenting the β-lactam ring to the organism as a template or trigger. Poor prescribing, or non-compliance on the part of the patient, would encourage bacterial mutation to produce effective resistance mechanisms or, more likely, facilitate the clonal expansion of a member of the population already with the genetic capabilities for methicillin resistance.154 But these are probably not the only factors by which MSSA becomes MRSA. It is also possible that the methicillin resistance genes are transferred to S. aureus from Staphylococcus epidermidis.138,155,156 Antibiotic resistance characteristics can be transferred between coagulase-negative and coagulase-positive staphylococci and this includes methicillin resistance.156 Most hospitals have endemic methicillin-resistant S. epidermidis (MRSE) in the environment as well as colonizing staff and patients,10,12,13,157 and newly admitted patients soon become colonized with multiply-resistant CNS.11,12,16,17 Patients may even be admitted with MRSE on the skin at the proposed operation site, which, the authors suggested, should question the use of prophylactic cephalosporins.22 This particular study concerned patients admitted for prosthetic hip implants, in whom it was shown that the most common post-operative infections were caused by methicillin-resistant coagulase-negative staphylococci.22 The consequence of cephalosporin prophylaxis is illustrated by two clinical studies of surgical patients, the first of which showed that MRSE was detected in high numbers on the skin of surgical patients within 5 days of exposure to per-operatively administered cephalosporins.18 The second showed that just three doses of cefuroxime encouraged the appearance of MRSE from aortic graft recipients within 1 week.158 Once colonized, further usage of β-lactam antibiotics exerts the selection pressure required for continued increase in methicillin-resistant staphylococci.14,15,137,147,151 As it is the case that all persons are colonized with S. epidermidis and one in three persons are colonized with S. aureus, the propensity for selection and spread of methicillin-resistant staphylococci and the potential for genetic exchange between staphylococcal species becomes immediately apparent.137,155,156 There is a direct association between MRSA and cephalosporins. Asensio et al.159 showed that patients who had received treatment for >5 days with cephalosporins were three times more likely to acquire MRSA than those who had not received these agents. This agrees with other studies, which detail a significant association of cephalosporins with the acquisition of MRSA.149–151,160 Conversely, a study demonstrating the effects of reducing cephalosporin usage in three acute medical wards for the elderly showed that the number of MRSA infections was reduced by half; there was also a 42% drop in the number of C. difficile infections.66 Another reported a decline in the number of MRSA isolates from 35% to 23%, following the introduction of control strategies including a decision to decrease the use of cephalosporins in favour of piperacillin– tazobactam.161 MRSA appears to be a sensitive indicator of the quality of hospital hygiene overall,162 as it is associated with other hospital organisms of concern.66,81,161 If a hospital manages to control MRSA, it controls other hospital organisms as well.162 Recently, there has been a report published detailing the deaths of four children from MRSA infections, three of whom had originally received a cephalosporin.163 Cephalosporins are only poorly active against MRSA;164–166 it is possible that usage of these antibiotics not only selects for MRSA, but encourages enhanced virulence.151,161 Certainly, prophylactic cefazolin is a risk factor for deep surgical wound infections with borderline oxacillin-susceptible strains of S. aureus.167 GRE Enterococci have also become a significant cause of hospital-acquired infection over the past 20 years.4 Natural resistance to penicillin and cephalosporins has been further complicated by additional resistance to amoxicillin, co-amoxiclav, gentamicin and now glycopeptides.53,168 There are virtually no antibiotics available for the treatment of clinically significant resistant enterococci and no means whereby asymptomatic carriers can be cleared.28,169 The association between cephalosporin therapy and enterococcal overgrowth has already been discussed. It follows, therefore, that vancomycin-resistant enterococci (VRE) are also associated with cephalosporin usage.170,171 A recent report describes how hyperendemic VRE in a haematology unit was effectively eradicated by changing from ceftazidime to piperacillin–tazobactam as first-line treatment for febrile neutropenics. The reintroduction of ceftazidime was accompanied by a return of VRE, despite continued attention to hygiene and surveillance.170 A study previously mentioned witnessed a drop in the number of VRE isolates from 16% to 5% after restricting cephalosporins in favour of piperacillin–tazobactam.161 Outbreaks of VRE may be controlled by switching from cephalosporins to aztreonam,172 or from cephalosporins to aminoglycosides.173 VRE are also linked with the use of glycopeptides in hospitals151,168,174 and in animals,174,175 and this has been assumed to be the most important factor in the selection of these organisms.171 However, if the indications for vancomycin therapy are examined, it is apparent that some of these indications are actually generated by the use of cephalosporins,3,6,151,176 i.e. there is not only a direct association of cephalosporins with VRE, but an indirect one, whereby cephalosporins select other organisms that require treatment with vancomycin, which then leads to the selection of VRE.151 Methicillin-resistant staphylococci, for example, already linked to the widespread use of β-lactam antibiotics, including cephalosporins, warrant treatment with iv vancomycin for seriously infected patients.23,168,177 Even more vancomycin is used, for prophylactic purposes, if patients at risk are admitted to a hos- pital with endemic methicillin-resistant staphylococci.22,26 Glycopeptide-susceptible enterococci, selected by cephalosporin use, occasionally require treatment with vancomycin, especially if resistant to aminoglycosides.3,52 Patients with C. difficile colitis, another sequelae of cephalosporin therapy, also require treatment with vancomycin.171,178 Thus, cephalosporin use is associated with several different organisms, the management of which may include vancomycin. Increased vancomycin usage could then select for vancomycin-resistant organisms including VRE. The C. difficile scenario can be considered further regarding the evolution of VRE, because a patient treated with cephalosporin antibiotics suffers concurrent overgrowth of both C. difficile and enterococci.176,179 If severe diarrhoea ensues, therapy is usually with oral vancomycin. Thereby an abundance of naturally resistant enterococci are exposed to non-absorbable vancomycin and the gut provides an excellent site for selection.46 (Vancomycin-resistant pediococci, leuconostoc and lactobacilli inhabit the mouth, gut and genital tract, but these do not appear to be the source of the genes encoding acquired resistance in enterococci.180) When faeces are screened for VRE, those patients found to be positive are often colonized with C. difficile as well; some even have MRSA to complete the package.179 In summary, therefore, it may be that heavy usage of cephalosporins is the main driving force behind the increasing prevalence of VRE, rather than glycopeptides. This hypothesis is also supported by studies that report that parenteral vancomycin does not appear to be an important risk factor for acquisition of VRE,181,182 nor did the administration of copious amounts of oral vancomycin for an outbreak of C. difficile appear to generate a problem with VRE.173 Furthermore, successful restriction of vancomycin prescribing has had no effect upon the occurrence of VRE in some centres.183,184 An added complication regarding VRE in a hospital concerns its ability to survive long-term in the environment.185 It is worth promoting environmental hygiene in a hospital, especially since there are no effective protocols for clearing VRE from the human gastrointestinal tract.28,186 The hospital environment may not be so temperate as the human gut, but may still provide an appropriate medium whereby organisms are able to transfer resistance genes.187,188 Exchange of genes between Gram-positive organisms is well documented.189,190 MRSA is another organism noted for its ability to survive in the hospital environment, but there is no evidence that resistant enterococci have contributed towards the appearance of glycopeptide-tolerant strains of MRSA.191 In vitro studies on the pharmacodynamic effects of cephalosporins So far, this review has focused upon the problem of selection and overgrowth of organisms associated with cephalosporin therapy. A common theme underlying this problem is the inability of these antibiotics to eradicate effectively key organisms, thus encouraging survival either with or without enhanced resistance to antibiotics. In this context, recent work on the mechanism of action of cephalosporin antibiotics offers some in vitro explanations for these clinical observations.192 Microscopic studies on the effect of β-lactam antibiotics on the bacterial cell at concentrations in excess of the MIC are able to distinguish between amoxicillin and cefalexin.193 The sequence of events is inhibition of cell division followed by lysis; this occurs very quickly with amoxicillin, as cell growth barely reaches two cell units in length before the onset of lysis. With cefalexin, however, there is a significant period of filamentous growth before the cell lyses, usually as a result of a sudden rupture of the cell wall. Filaments can be observed in clinical specimens from patients with Gram-negative infections treated with a variety of β-lactams, and, in particular, the aminothiazolyl cephalosporins, e.g. cefuroxime, cefotaxime, ceftazidime and ceftriaxone. This property has prompted one author to state that bacterial growth is not actually inhibited by the filament-forming antibiotics and it follows that overall cell wall synthesis is not inhibited to any significant extent either.194 It could also be said that the time utilized for filament-forming by the cephalosporins is time available for antimicrobial resistance induction, whereas the use of other agents, which induce early cell death, would reduce the risk of such an event. Filamentous cells that develop in the presence of cephalosporins do eventually lyse as a result of a sudden rupture of the cell wall, usually at a point where cell division would normally have taken place.193 Round cell formation and rapid lysis can be achieved by using higher concentrations of predominantly filament-forming antibiotics.192,195 These antibiotics therefore do not precipitate the rapid cell lysis and bactericidal effects more usually associated with β-lactam agents, but promote the generation of aberrant forms that are able to survive in vivo. This may have clinical implications; first, as some bacteria may persist in patients following a course of one of these antibiotics; secondly, as survival may include the generation of tolerant or even resistant progeny, and thirdly, when assessing endotoxin release following exposure to antibiotics.196 Filament formation leads to a rapid increase in endotoxin production and, ultimately, endotoxin release when these cells lyse.197 There are several studies to support this.198–200 Higher doses of filament-forming antibiotics may alternatively produce the more fragile spheroplasts, which would tend to lyse and thus reduce the propensity for endotoxic shock.196,201 It is possible, therefore, that the choice and dose of an antimicrobial agent for a patient with septic shock could be clinically crucial.196 Conclusion This review has attempted to piece together some of the suspicions surrounding a very widely used class of antibiotics. There is strong suggestive evidence that cephalosporins have played a major role in encouraging the organisms discussed. Countries, and even individual hospitals, that have enforced low usage of cephalosporins through education, strict antibiotic policies and prescribing penalties, are currently experiencing relatively low rates of multiply-resistant organisms.66,135,141,142,161,202 Countries where cephalosporins are used more often have much higher rates of resistance.122,137,141,203 It is, however, difficult to determine whether it is specific restriction of cephalosporin antibiotics in isolation that is responsible for the lower rates of resistance, or, indeed, an overall effect from controlling all antibiotic classes.135 In defence of the former view, most of the references cited specifically target cephalosporins as key players in the link between antibiotic usage and prevalence of multiply-resistant organisms. Compounding the problem is the fact that microbiologists have yet to define fully the mechanisms linking antibiotic usage and antibiotic resistance. Prescribing colleagues will almost certainly question how just one group of antibiotics alone, within the extensive β-lactam class, could be the most important driving force behind the continuing increase in resistant organisms, even allowing for broad-spectrum activity and popularity.83,204,205 Convincing clinicians that antibiotic therapy should be more closely tailored to the patient requires scientific proof and this is not yet evident. Changing current antibiotic prescribing practices demands a strong microbiology presence, robust antibiotic policies, education and laboratory support, as well as a more careful evaluation of the infected patient and potential pathogen, confirmed or otherwise.206 If there is difficulty in convincing colleagues of the clinical and long-term benefits of decreasing cephalosporin use, then the funders of healthcare may offer a view. Aside from the cost benefits of reducing the amount of these drugs purchased, there are substantial savings to be made from lower numbers of patients who require treatment for the consequences of overgrowth resulting from cephalosporin therapy.81,207 It has been suggested that the clinical freedom enjoyed by the medical profession to prescribe what they like, when they like, should be reviewed for the prescription of antimicrobials.208 Even experienced practitioners may not realize that giving a patient antibiotics affects not just that patient, but also their environment, and all the other people that come into contact with that environment.204,209,210 Removing the right to prescribe antimicrobials freely would divide the medical profession and place a monumental burden upon microbiology and infectious disease specialists. There may also be repercussions for dentists and nurse prescribers. Even if this policy was implemented, inadequate infection control and antibiotic practices elsewhere in the world would erode any progress made in halting the increase of multiply-resistant organisms. The World Health Organization (WHO) must take some responsibility in promoting international discussion on antimicrobial use throughout the world. A multifaceted approach to the control of multiply-resistant organisms is required.202 There are a variety of strategies, some of which have already been mentioned, i.e. antibiotic policies, judicious use of antimicrobials by clinicians, laboratory support, WHO involvement and a strengthening of the role of microbiologists and infectious diseases physicians. Education for everyone is vitally important and in particular, perhaps, for medical students, for whom microbiology teaching should be re-prioritized within the undergraduate curriculum.211 Pharmacists play an important role in restricting over-the-counter sales and in the advice they offer. In the hospitals, they audit prescribing, evaluate adherence to policies and formulary and issue advice on iv-to-oral and antibiotic-stop mechanisms. The microbiology laboratory cannot provide instant identification of all microorganisms, but there are an increasing number of rapid diagnostic techniques available and 24 h processing of non-urgent specimens from high-risk patients can be introduced in order to avoid a sample languishing until the next working day. Laboratory computers should provide the data required for multiple audit and surveillance strategies for infection control. Pharmaceutical research, better definitions of infection and the dangers of prolonged prescribing are other potential control issues.202 In defence of the cephalosporin antibiotics, they provide useful activity against a number of common pathogens, and their low toxicity reassures clinicians and obviates the need for serum levels.212 Patients allergic to penicillin sometimes rely upon a cephalosporin as the only agent available to them. They should not be used for routine prophylaxis, however, but have their efficacy preserved with more rational prescribing.22,213,214 There may well be an argument for revising the recommended adult doses of, in particular, the aminothiazolyl cephalosporins. Reduced bactericidal activity leading to the selection phenomena described may relate to inadequate dosing rather than an inherent therapeutic deficit. Tissue penetration and concentration at the site of infection are other factors to consider. It is also pertinent to say that in the absence of cephalosporins, greater use of other antibiotics would have been required. Not only would these have very likely generated their own particular selection strategies, but also some agents would have almost certainly produced considerable toxic effects, far more so than the cephalosporins. It is unlikely, however, that we would have seen the prolific rise of multiply-resistant organisms if the cephalosporins had never been introduced. This is because few of the existing agents offered such broad-spectrum activity, with such low toxicity, and consequently would not have been universally prescribed. A greater range of antibiotics would have been utilized, diffusing the selection potential. It is the popularity of the cephalosporins, perhaps, that has become their downfall. Resistance inevitably follows the introduction of a new antimicrobial. In intensive care units, the original promise offered by cephalosporins as broad-spectrum therapy was almost immediately eroded by the appearance of resistant organisms, and their use was supplanted by the use of quinolones. The legacy of heavy usage of these drugs, however, resulted in the appearance of multiply-resistant Acinetobacter. Now S. maltophilia flourishes, following the introduction of the carbapenems.215 This ominous progression, played out over the past 20 years, can be likened to a worldwide chess game; as one piece is captured, another moves to threaten.216 If we therefore shift prescribing choice away from the cephalosporins to another antibiotic class, bacteria will evolve resistance mechanisms to the new group chosen.46 Resistance is the price one pays for having an antibiotic and using it, because nature abhors a vacuum and will fill it up if it can.134 Ultimately, the future therapy of infection may almost certainly depend upon the immunologists, with construction of vaccines against virulence determinants or continued work on the development of cytokine inhibitors.210 The latter are already showing positive benefits for patients in ITU.217,218 In conclusion, the selection pressure created by heavy usage of cephalosporin antibiotics over the last 20 years has generated a plethora of multiply-resistant organisms. The possible links between C. difficile, VRE and MRSA serve as a warning for potentially untreatable infection—with ESBLC providing the Gram-negative equivalent. The risks posed by overuse of cephalosporins remain only speculative, unless specific proof is forthcoming. By then, though, we may be contemplating the post-antibiotic era. 1 *Tel: +44-1389-754121; Fax: +44-1389-603910; E-mail: stephanie.dancer@vol.scot.nhs.uk Thanks are due to Mrs Su Byrne for secretarial services and Dr Shelley Heard for original teaching on antibiotics. References 1 Livermore, D. M. ( 1991 ). Mechanisms of resistance to β-lactam antibiotics. Scandinavian Journal of Infectious Diseases Supplement 78 , 7 –16. 2 Wise, R. (1997). β-Lactams: cephalosporins. In Antibiotics and Chemotherapy, 7th edn, (O'Grady, F., Lambert, P. H., Finch, R. G., Greenwood, D., Eds), pp. 202–55. Churchill Livingstone, New York. 3 Pallares, R., Pujol, M., Pena, C., Ariza, J., Martin, F. & Gudiol, F. ( 1993 ). Cephalosporins as risk factors for nosocomial Enterococcus faecalis bacteraemia. A matched case–control study. Archives of Internal Medicine 153 , 1581 –6. 4 Moellering, R. C. ( 1992 ). Emergence of Enterococcus as a significant pathogen. Clinical Infectious Diseases 14 , 1173 –6. 5 Bamberger, D. M. & Dahl, S. L. ( 1992 ). Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital. Archives of Internal Medicine 152 , 554 –7. 6 Pallares, R., Dick, R., Wenzel, R., Adams, J. R. & Nettleman, M. D. ( 1993 ). Trends in antimicrobial utilization at a tertiary teaching hospital during a 15 year period (1978–1992). Infection Control and Hospital Epidemiology 14 , 376 –82. 7 Nicolle, L. E. ( 1988 ) Prior antimicrobial therapy and resistance of Enterobacter, Citrobacter and Serratia to third generation cephalosporins. Journal of Hospital Infection 11 , 321 –7. 8 Follath, F., Costa, E., Thommen, A., Frei, R., Burdeska, A. & Meyer, J. ( 1987 ). Clinical consequences of development of resistance to third generation cephalosporins. European Journal of Clinical Microbiology 6 , 446 –50. 9 Salacata, A. & Chow, J. W. ( 1993 ). Cephalosporin therapeutics for intensive care infections. New Horizon 1 , 181 –6. 10 Maki, D. G. (1984). Comparison of organisms carried on the hands of hospital (ICV) personnel and non-medical control personnel. In Program and Abstracts of the Twenty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 1984. Abstract 521. American Society for Microbiology, Washington, DC. 11 Powell, M. & Sanderson, P. J. ( 1987 ). Resistant coagulase-negative Staphylococci in hospital patients. Journal of Hospital Infection 9 , 48 –53. 12 Thurn, J. R., Crossley, K. B., Gerdst, A. & Baken, L. ( 1992 ). Dynamics of coagulase-negative staphylococcal colonisation in patients and employers in a surgical intensive care unit. Journal of Hospital Infection 20 , 247 –55. 13 Maki, D. G., Alvarado, C. J., Hassemer, C. A. & Zilz, M. A. ( 1982 ). Relation of the inanimate environment to endemic nosocomial infections. New England Journal of Medicine 307 , 1562 –66. 14 Lyytikainen, O., Vaara, M., Jarviluoma, E., Rosenqvist, K., Tiittanen, L. & Valtonen, V. ( 1996 ). Increased resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12-year period. European Journal of Clinical Microbiology and Infectious Diseases 15 , 133 –8. 15 Mouton, R. P., Hermans, J., Simoons-Smith, A. M., Hoogcamp-Korstanje, J. E. & Van Kungeren, B. ( 1990 ). Correlations between consumption of antibiotics and methicillin-resistance in coagulase-negative staphylococci. Journal of Antimicrobial Chemotherapy 26 , 573 –83. 16 Terpstra, S., Noordhoek, G. T., Voesten, H. G. J., Hendriks, B. & Degener, J. E. ( 1999 ). Rapid emergence of resistant coagulase-negative staphylococci on the skin after antibiotic prophylaxis. Journal of Hospital Infection 43 , 195 –202. 17 Archer, G. L. & Armstrong, B. C. ( 1983 ). Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis. Journal of Infectious Diseases 147 , 642 –9. 18 Kernodle, D. S., Barg, N. L. & Kaiser, A. B. ( 1988 ). Low-level colonization of hospitalised patients with methicillin-resistant coagulase-negative staphylococci and emergence of the organisms during surgical antimicrobial prophylaxis. Antimicrobial Agents and Chemotherapy 32 , 202 –8. 19 Edlund, C. & Nord, C. E. ( 1991 ). A model of bacterial– antimicrobial interactions: the case of oropharyngeal and gastrointestinal microflora. Journal of Chemotherapy 3 , 196 –200. 20 Chin, N. X., Neu, N. M. & Neu, H. C. ( 1990 ). Activity of cephalosporins against coagulase-negative staphylococci. Diagnostic Microbiology and Infectious Disease 13 , 67 –9. 21 Monsen, T., Ronnmark, M., Olofsson, C. & Wistrom, J. ( 1999 ). Antibiotic susceptibility of staphylococci isolated in blood cultures in relation to consumption in hospital wards. Scandinavian Journal of Infectious Diseases 31 , 399 –404. 22 James, P. J., Butcher, I. A., Gardner, E. R. & Hamblen, D. L. ( 1994 ). Methicillin-resistant Staphylococcus epidermidis in infection of hip arthroplasties. Journal of Bone and Joint Surgery 76 , 725 –7. 23 Hamory, B. H., Parisi, J. T. & Hutton, J. P. ( 1987 ). Staphylococcus epidermidis: a significant nosocomial pathogen. Journal of Infection Control 15 , 59 –74. 24 Raad, I., Davis, S., Khan, A., Tarrand, J., Elting, L. & Bodey, G. P. ( 1992 ). Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infection Control and Hospital Epidemiology 13 , 215 –21. 25 Gorbach, S. L. ( 1989 ). The role of cephalosporins in surgical prophylaxis. Journal of Antimicrobial Chemotherapy 23 , Suppl. D, 61 –70. 26 Mini, E., Nobili, S. & Periti, P. ( 1997 ). Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis? Drugs 54 , Suppl. 6, 39 –52. 27 Sanderson, P. J. ( 1998 ). Prophylaxis in orthopaedic implant surgery—should we use a glycopeptide? Journal of Antimicrobial Chemotherapy 41 , 322 –5. 28 Hospital Infection Control Practices Advisory Committee. ( 1995 ). Recommendations for preventing the spread of vancomycin resistance. Infection Control and Hospital Epidemiology 16 , 105 –13. 29 Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T. & Tenover, F. C. ( 1997 ). MRSA clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40 , 135 –46. 30 Leigh, D. A., Walsh, B., Leung, A., Tait, S., Peatey, K. & Hancock, P. ( 1990 ). The effect of cefuroxime axetil on the faecal flora of healthy volunteers. Journal of Antimicrobial Chemotherapy 26 , 261 –8. 31 Paull, A. & Morgan, J. R. ( 1986 ). Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 18 , 635 –9. 32 Edgeworth, J. D., Treacher, D. F. & Eykyn, S. J. ( 1999 ). A 25-year study of nosocomial bacteremia in an adult intensive care unit. Critical Care Medicine 27 , 1421 –8. 33 Jones, R. N. ( 1992 ). The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diagnostic Microbiology and Infectious Diseases 15 , Suppl. 2, 3S –10S. 34 Warren, J. W., Anthony, W. C., Hoopes, J. M. & Muncie, H. L. ( 1982 ). Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients. Journal of the American Medical Association 248 , 454 –8. 35 Khardori, N., Elting, L., Wong, E., Schable, B. & Bodey, G. P. ( 1990 ). Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients. Reviews of Infectious Diseases 12 , 997 –1003. 36 Pedersen, S. S., Koch, C., Hoiby, N. & Rosendal, K. ( 1986 ). An epidemic spread of multi-resistant Pseudomonas aeruginosa in a cystic fibrosis centre. Journal of Antimicrobial Chemotherapy 17 , 505 –16. 37 Denton, M. & Kerr, K. G. ( 1998 ). Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clinical Microbiology Reviews 11 , 57 –80. 38 Nordmann, P. & Guibert, M. ( 1998 ). Extended-spectrum β-lactamases in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 42 , 128 –31. 39 Coronado, V. G., Edwards, J. R., Culver, D. H. & Gaynes, R. P. ( 1995 ). Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. National Nosocomial Infections Surveillance (NNIS) System. Infection Control and Hospital Epidemiology 16 , 71 –5. 40 Grassi, G. G. & Grassi, C. ( 1993 ). Cefepime: overview of activity in vitro and in vivo. Journal of Antimicrobial Chemotherapy 32 , Suppl. B, 87 –94. 41 Edlund, C., Stark, C. & Nord, C. E. ( 1994 ). The relationship between an increase in β-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. Journal of Antimicrobial Chemotherapy 34 , 127 –38. 42 George, R. C. & Uttley, A. H. C. ( 1989 ). Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s. Epidemiology and Infection 103 , 403 –13. 43 Magnussen, C. R. & Cave, J. ( 1988 ). Nosocomial enterococcal infections: association with use of third-generation cephalosporin antibiotics. American Journal of Infection Control 16 , 241 –5. 44 Guggenbichler, J. P., Allerberger F. J. & Dierich, M. ( 1986 ). Influence of cephalosporins III generation with varying biliary excretion on faecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatrie und Padologie 21 , 335 –42. 45 Suppola, J. P., Volin, L., Valtonen, V. V. & Vaara, M. ( 1996 ). Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clinical Infectious Diseases 23 , 694 –7. 46 Gentry, L. O. ( 1991 ). Bacterial resistance. Orthopedic Clinics of North America 22 , 379 –88. 47 van der Waaij, D. ( 1987 ). Colonisation resistance of the digestive tract—mechanism and clinical consequences. Nahrung 31 , 507 –17. 48 de Vries-Hospers, H. G., Tonk, R. H. & van der Waaij, D. ( 1991 ). Effect of intramuscular ceftriaxone on aerobic oral and faecal flora of 11 healthy volunteers. Scandinavian Journal of Infectious Diseases 23 , 625 –33. 49 Manzella, J., Benenson, R., Pellerin, G., Kellogg, J., Bell, T., Robertson, M. & Pope, D. ( 2000 ). Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia. Infection Control and Hospital Epidemiology 21 , 789 –91. 50 van der Waaij, D., Hofstra, H. & Wiegersma, N. ( 1982 ). Effect of beta-lactam antibiotics on the resistance of the digestive tract of mice to colonization. Journal of Infectious Diseases 146 , 417 –22. 51 van der Waaij, D. ( 1985 ). Selective decontamination of the digestive tract with oral aztreonam and temocillin. Reviews of Infectious Diseases 7 , Suppl. 4, S628 –34. 52 Woodford, N., Morrison, D., Johnson, P. & George, R. C. ( 1993 ). Antimicrobial resistance amongst enterococci isolated in the United Kingdom, a reference laboratory perspective. Journal of Antimicrobial Chemotherapy 32 , 344 –6. 53 Uttley, A. H. C., Collins, C. H., Naidoo, J. & George, R. C. ( 1988 ). Vancomycin-resistant enterococci. Lancet i , 57– 8. 54 Riley, T. V. ( 1996 ). Clostridium difficile: a high-cost nosocomial pathogen. Culture 17 , 2 –4. 55 Ambrose, N. S., Johnson, M., Burdon, D. W. & Keighley, M. R. B. ( 1985 ). The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. Journal of Antimicrobial Chemotherapy 15 , 319 –26. 56 de Lalla, F., Privitera, G., Ortisi, G., Rizzardini, G., Santoro, D., Pagano, A. et al. ( 1989 ). Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital. Journal of Antimicrobial Chemotherapy 23 , 623 –31. 57 Impallomeni, M., Galletly, N. P., Wort, J., Starr, J. M. & Rogers, T. R. ( 1995 ). Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. British Medical Journal 311 , 1345 –6. 58 Chachaty, E., Depitre, C., Mario, N., Bourneix, C., Saulnier, P., Corthier, G. et al. ( 1992 ). Presence of Clostridium difficile and antibiotic and beta-lactamase activities in faeces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo. Antimicrobial Agents and Chemotherapy 36 , 2009 –13. 59 McFarland, L. V., Mulligan, M. E., Kwok, R. Y. & Stamm, N. E. ( 1989 ). Nosocomial acquisition of Clostridium difficile infection. New England Journal of Medicine 320 , 204 –10. 60 Zadik, P. M. & Moore, A. P. ( 1998 ). Antimicrobial association of an outbreak of diarrhoea due to Clostridium difficle. Journal of Hospital Infection 39 , 189 –93. 61 Wilcox, M. H., Cunniffe, J. G., Trundle, C. & Redpath, C. ( 1996 ). Financial burden of hospital-acquired infection. Journal of Hospital Infection 34 , 23 –30. 62 Wilcox, M. H. & Smyth, E. T. M. ( 1998 ). Incidence and impact of Clostridium difficile infection in the UK, 1993–1996. Journal of Hospital Infection 39 , 181 –7. 63 The British Thoracic Society. ( 1993 ). Guidelines for the management of community acquired pneumonia in adults admitted to hospital. British Journal of Hospital Medicine 49 , 346 . 64 Spencer, R. C. ( 1998 ). The role of antimicrobial agents in the etiology of Clostridium difficile-associated disease. Journal of Antimicrobial Chemotherapy 41 , Suppl. C, 21 –7. 65 Wort, S. J. & Rogers, T. R. ( 1998 ). Community-acquired pneumonia in elderly people. British Medical Journal 316 , 1690 . 66 Stone, S. P., Beric, V., Quick, A., Balestrini, A. & Kibbler, C. ( 1998 ). The effect of an enhanced infection-control policy on the incidence of Clostridium difficile infection and methicillin-resistant Staphylococcus aureus colonization in acute elderly medical patients. Age and Ageing 27 , 561 –8. 67 McNulty, C., Logan, M., Donald, I. P., Ennis, D., Taylor, D., Baldwin, R. N. et al. ( 1997 ). Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. Journal of Antimicrobial Chemotherapy 40 , 707 –11. 68 Bross, J., Talbot, G. H., Maislin, G., Hurwitz, S. & Strom, B. L. ( 1989 ). Risk factors for nosocomial candidemia: a case–control study in adults without leukaemia. American Journal of Medicine 87 , 614 –20. 69 Wey, S. B., Mori, M., Pfaller, M. A., Woolson, R. F. & Wenzel, R. P. ( 1989 ). Risk factors for hospital-acquired candidaemia. A matched case–control study. Archives of Internal Medicine 149 , 2349 –53. 70 Kinsman, O. S. & Pitblado, K. ( 1989 ). Candida albicans gastrointestinal colonization and invasion in the mouse: effect of antibacterial dosing, antifungal therapy and immunosuppression. Mycoses 32 , 664 –74. 71 Samonis, G., Dassiou, M. & Anastassiadou, H. ( 1994 ). Antibiotics affecting gastrointestinal colonization of mice by yeasts. Journal of Chemotherapy 6 , 50 –2. 72 Thomakos, N., Maraki, S., Liakakos, T., Macheras, A., Kanakavi, S., Marinis, E. et al. ( 1998 ). Effect of cefamandole, cefuroxime and cefoxitin on yeast fecal flora of surgical patients. Chemotherapy 44 , 324 –7. 73 Gubbins, P. O., McConnell, S. A. & Penzak S. R. ( 1999 ). Current management of funguria. American Journal of Health Systems and Pharmacy 56 , 1929 –35. 74 Nassoura, Z., Ivatury, R. R., Simon, R. J., Jabbour, N. & Stahl, W. M. ( 1993 ). Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy. Journal of Trauma 35 , 290 –5. 75 Wade, J. C. (1993). Epidemiology of Candida infections. In Candidiasis, 2nd edn, (Bodey, G. P., Ed.), pp. 85–107. Raven Press, New York. 76 Pfaller, M. A. ( 1995 ). Epidemiology of candidiasis. Journal of Hospital Infection 30 , Suppl., 329 –38. 77 Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T. et al. ( 1991 ). Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. American Journal of Medicine 91 , Suppl. 3B, 86S –89S. 78 Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E. et al. ( 1999 ). Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagnostic Microbiology and Infectious Disease 33 , 217 –22. 79 Schaberg, D. R., Culver, D. H. & Gaynes, R. P. ( 1991 ). Major trends in the microbial etiology of nosocomial infection. American Journal of Medicine 91 , Suppl. 3B, 72S –75S. 80 Swartz, M.N. ( 1994 ). Hospital-acquired infections: diseases with increasingly limited therapies. Proceedings of the National Academy of Sciences, USA 91 , 2420 –7. 81 Frank, M. O., Batteiger, B. E., Sorensen, S. J., Hartstein, A. I., Carr, J. A., McComb, J. S. et al. ( 1997 ). Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clinical Performance and Quality Health Care 5 , 180 –8. 82 Eggimann, P., Glauser, M. P., Auon, M., Meunier, F. & Cacandra, T. ( 1993 ). Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. Journal of Antimicrobial Chemotherapy 32 , Suppl. B, 151 –63. 83 Gould, I. M. ( 1999 ). A review of the role of antibiotic policies in the control of antibiotic resistance. Journal of Antimicrobial Chemotherapy 43 , 459 –65. 84 Medeiros, A. A. ( 1984 ). Beta-lactamases. British Medical Bulletin 40 , 18 –27. 85 Dancer, S. J., Shears, P. & Platt, D. J. ( 1997 ). Isolation and characterization of coliforms from glacial ice and water in Canada's High Arctic. Journal of Applied Microbiology 82 , 597 –609. 86 Livermore, D. M. ( 1987 ). Clinical significance of beta-lactamase induction and stable depression in Gram-negative rods. European Journal of Clinical Microbiology 6 , 439 –45. 87 Amyes, S. G. B. & Miles, R. S. ( 1998 ). Extended-spectrum β-lactamases: the role of inhibitors in therapy. Journal of Antimicrobial Chemotherapy 42 , 415 –7. 88 Pechere, J. C. ( 1989 ). Emergence of resistance in Gramnegative bacilli during beta-lactam therapy: a challenge for the future. European Journal of Cancer and Clinical Oncology 25 , Suppl. 2, S17 –23. 89 Bedenic, B. ( 1999 ). Molecular and genetic characterization of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae. ISID News 5 , 4 –7. 90 Amyes, S. G. B., Payne, D. J. & du Bois, S. K. ( 1992 ). Plasmid-mediated beta-lactamases responsible for penicillin and cephalosporin resistance. Journal of Medical Microbiology 36 , 6 –9. 91 Jacoby, G. A. ( 1994 ). Genetics of extended-spectrum betalactamases. European Journal of Clinical Microbiology and Infectious Diseases 13 , Suppl. 1, S2 –11. 92 Murray, P. R., Granich, G. G., Krogstad, D. J. & Niles, A. C. ( 1983 ). In-vivo selection of resistance to multiple cephalosporins by Enterobacter cloacae. Journal of Infectious Diseases 147 , 590 . 93 Courcol, R. J., Pinkas, M. & Martin, G. R. ( 1989 ). A seven-year survey of antibiotic susceptibility and its relationship with usage. Journal of Antimicrobial Chemotherapy 23 , 441 –521. 94 Mulgrave, L. ( 1991 ). The changing ecology of hospital bacteria and the selective role of cephalosporins. Epidemiology and Infection 106 , 121 –32. 95 Sanders, W. E. & Sanders, C. C. ( 1988 ). Inducible β-lactamases: clinical and epidemiological implications for use of newer cephalosporins. Reviews of Infectious Diseases 10 , 830 –8. 96 Chow, J., Fine, M. J., Shlaes, D. M., Quinn, J. P., Hooper, D. C., Johnson, M. P. et al. ( 1991 ). Enterobacter bacteremia: clinical feature and emergence of resistance during therapy. Annals of Internal Medicine 115 , 585 –90. 97 Ballow, C. H. & Schentag, J. J. ( 1992 ). Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagnostic Microbiology and Infectious Disease 15 , 37S –42S. 98 Karas, J. A., Pillay, D. G., Muckart, D. & Sturm, A. W. ( 1996 ). Treatment failure due to extended-spectrum β-lactamases. Journal of Antimicrobial Chemotherapy 37 , 203 –4. 99 Koontz, F. P., Jones, R. N. & Wenzel, R. P. (1990). Antibiotic resistance: experience at the University of Iona Hospitals and Clinics. In Emerging Trends in Gram-Negative Resistance: A New Concern for Critical Care Medicine, (Wayne, N. J., Ed.), pp. 16–9. Lederle Laboratories. 100 Rice, L. B., Willey, S. H., Papanicolaou, G. A., Medeiros, A. A., Eliopoulos, G. M., Moellering, R. C. et al. ( 1990 ). Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrobial Agents and Chemotherapy 34 , 2193 –9. 101 Meyer, K. S., Urban, C., Eagan, J. A., Berger, B. J. & Rahal, J. J. ( 1993 ). Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Annals of Internal Medicine 119 , 353 –8. 102 Quinn, J. P. ( 1994 ). Clinical significance of extendedspectrum β-lactamases. European Journal of Clinical Microbiology and Infectious Diseases 13 , Suppl. 1, S39 –42. 103 Decker, M. D. & Schaffner, W. (1992). The relationship between the hospital and the community. In Hospital Infections, (Bennett, J. V. & Brachman, P. S., Eds), pp. 221–30. Little Brown, Boston. 104 Weinstein, R. A. ( 1987 ). Resistant bacteria and infection control in the nursing home and hospital. Bulletin of the New York Academy of Medicine 63 , 337 –44. 105 Appelbaum, P. C. ( 1992 ). Antimicrobial resistance to Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15 , 77 –83. 106 Doern, G. V., Brueggemann, A., Holley, H. P. & Rauch, A. M. ( 1996 ). Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994–1995: results of a thirty-centre national surveillance study. Antimicrobial Agents and Chemotherapy 40 , 1208 –13. 107 Jacobs, M. R., Koornhof, H. J., Robins-Browne, R. M., Stevenson, C. M., Vermaak, Z. A., Freiman, I. et al. ( 1978 ). Emergence of multiply resistant pneumococci. New England Journal of Medicine 299 , 735 –40. 108 Negri, M. C., Morosini, M. I., Loza, E. & Baquero, F. ( 1994 ). In vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant Streptococcus pneumoniae populations. Antimicrobial Agents and Chemotherapy 38 , 122 –5. 109 Goldstein, F. W. ( 1999 ). Penicillin-resistant Streptococcus pneumoniae: selection by β-lactam and non β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 44 , 141 –4. 110 Allen, K. D. & Anson, J. J. ( 1996 ). Prevalence of antibiotic resistance in pneumococci is higher in Merseyside. British Medical Journal 313 , 820 . 111 Nava, J. M., Bella, F., Garau, J., Lite, J., Morera, M.-A., Marti, C. et al. ( 1994 ). Predictive factors for invasive disease due to penicillin resistant Streptococcus pneumoniae: a population based study. Clinical Infectious Diseases 19 , 884 –90. 112 Baquero, F., Martinez-Beltran, J. & Loza, E. ( 1991 ). A review of antibiotic resistant patterns of S. pneumoniae in Europe. Journal of Antimicrobial Chemotherapy 28 , Suppl. C, 31 –8. 113 Coffey, T. J., Dowson, C. G., Daniels, M. & Spratt, B. G. ( 1995 ). Genetics and molecular biology of β-lactam resistant pneumococci. Microbial Drug Resistance 1 , 29 –34. 114 Verhaergen, J. & Verbist, L. ( 1998 ). In-vitro activity of 21 β-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 41 , 381 –5. 115 Perez-Trallero, E., Alkorta, M., Garcia-Arenzana, J. M., Iturzaeta, A. & Gomariz, M. ( 1998 ). In-vitro, in-vivo and ex-vivo studies with oral β-lactams against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 41 , 629 –34. 116 Baquero, F. ( 1996 ). Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on collaborative surveillance study. Journal of Antimicrobial Chemotherapy 38 , Suppl. A, 117 –32. 117 Cohen, R., Navel, M., Grumberg, J., Narcy, P., Boucherat, M., Geslin, P. et al. (1997). Single dose ceftriaxone (CRO) for acute otitis media in areas with high resistance to Streptococcus pneumoniae. In Program and Abstracts of the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract LM-34, p. 370. American Society for Microbiology, Washington, DC. 118 Arnold, K. E., Leggiadro, R. J., Breiman, R. F., Lipman, H. B., Schwartz, B., Appleton, M. A. et al. ( 1996 ). Risk factors for carriage of drug resistant Streptococcus pneumoniae among children in Memphis, Tennessee. Journal of Pediatrics 128 , 757 –64. 119 Ford, K. L., Mason, E. O., Kaplan, S. L., Lamberth, L. B. & Tillman, J. ( 1991 ). Factors associated with middle ear isolates of Streptococcus pneumoniae resistant to penicillin in a children's hospital. Journal of Pediatrics 119 , 941 –4. 120 Tan, T. Q., Mason, E. O. & Kaplan, S. L. ( 1993 ). Penicillin-resistant systemic pneumococcal infections in children: a retrospective case-control study. Pediatrics 92 , 761 –7. 121 Renneberg, J., Niemann, L. L. & Gutschik, E. ( 1997 ). Antimicrobial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents. Journal of Antimicrobial Chemotherapy 39 , 135 –40. 122 Marchese, A., Debbia, E. A., Arvigo, A., Pesce, A. & Schito, G. C. ( 1995 ). Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics. Journal of Antimicrobial Chemotherapy 36 , 833 –7. 123 Halls, G. A. ( 1993 ). The management of infections and antibiotic therapy: a European survey. Journal of Antimicrobial Chemotherapy 31 , 985 –1000. 124 Dabernat, H., Geslin, P., Megraud, F., Begue, P., Boulesteix, J., Dubreuil, C. et al. ( 1998 ). Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. Journal of Antimicrobial Chemotherapy 41 , 253 –8. 125 Sifaoui, F., Kitzis, M. D. & Gutmann, L. ( 1996 ). In vitro selection of one-step mutants of S. pneumoniae resistant to different oral β-lactams antibiotics is associated with alterations of PBP2x. Antimicrobial Agents and Chemotherapy 40 , 152 –6. 126 Bauernfeind, A., Jungwirth, R., Schweighart, S. & Theopold, M. ( 1990 ). Antibakterielle Aktivitat und β-Laktamase – Stabilitat von elf Oralcephalosporinen. Infection 18 , Suppl. 3, S155 –67. 127 Goldsmith, C. E., Moore, J. E. & Murphy, P. G. ( 1996 ). Prevalence of antibiotic resistance in pneumococci is higher in Northern Ireland. British Medical Journal 313 , 820 . 128 Granizo, J. J., Aguilar, L. L., Casal, J., Garcia-Rey, C., Dal-Re, R. & Baquero, F. ( 2000 ). Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolides and β-lactam consumption in Spain (1979–1997). Journal of Antimicrobial Chemotherapy 46 , 767 –73. 129 Arason, V. A., Kristinsson, K. G., Sigurdsson, J. A., Stefansdotir, G., Molstad, S. & Gudmundsson, S. ( 1996 ). Do antimicrobials increase the drainage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. British Medical Journal 813 , 387 –91. 130 Gehanno, P., N'Guyen, L., Derriennic, M., Pichon, F., Goehrs, J. M. & Berche, P. ( 1998 ). Pathogens isolated during treatment failures in otitis. Pediatric Infectious Diseases Journal 17 , 885 –90. 131 House of Lords Select Committee on Science and Technology. (1998). Resistance to Antibiotics and Other Antimicrobial Agents. Stationery Office, London. 132 Anonymous. ( 2000 ). Staphylococcus aureus bacteraemia: England and Wales. CDR Communicable Disease Report Weekly 10 , 143 –4. 133 Jevons, M. P. ( 1961 ). Celbenin-resistant staphylococci. British Medical Journal 1 , 124 –5. 134 Batchelor, F. R. (2000). Post penicillin antibiotics: from acceptance to resistance? In Wellcome Witnesses to Twentieth Century Medicine, 6th edn, (Tansey, E. M. & Reynolds, L. A., Eds), pp. 54. The Wellcome Trust, London. 135 Ayliffe, G. A. J. ( 1997 ). The progressive intercontinental spread of MRSA. Clinical Infectious Diseases 24 , Suppl. 1, S74 –9. 136 Dacre, J., Emmerson, A. M. & Jenner, E. A. ( 1986 ). Gentamicin–methicillin-resistant Staphylococcus aureus: epidemiology and containment of an outbreak. Journal of Hospital Infection 7 , 130 –6. 137 Yamaguchi, K. & Ohno, A. ( 1992 ). Consideration on MRSA infections in relation to modern chemotherapy. Nihon Rinsho 50 , 923 –31. 138 Ubukata, K., Nonoguchi, R., Dong Song, M., Matsuhashi, M. & Konno, M. (1990). Expression and inducibility of methicillin resistance encoded by a mecA gene in staphylococci. In Molecular Biology of the Staphylococci, (Novick, R. P., Ed.), pp. 471–89. VCH Publishers, New York. 139 Fukatsu, K., Saito, H., Matsuda, T., Ikeda, S., Furukawa, S. & Muto, T. ( 1997 ). Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Archives of Surgery 132 , 1320 –5. 140 Casewell, M. W. & Hill, R. L. R. ( 1986 ). The carrier state: methicillin resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 18 , 1 –12. 141 Voss, A., Milatovic, D., Wallrauch-Schwarz, C., Rosdahl, V. T. & Braveny, I. ( 1994 ). Methicillin-resistant Staphylococcus aureus in Europe. European Journal of Clinical Microbiology and Infectious Diseases 13 , 50 –5. 142 Voss, A. ( 1996 ). Staphylococcus aureus. Pan-European antibiotic resistance and infection control. Chemotherapie Journal 5 , 5 –6. 143 Saravolatz, L. D., Pohlod, D. & Arking, L. ( 1982 ). Community acquired MRSA infections: a new source for nosocomial outbreaks. Annals of Internal Medicine 97 , 325 –9. 144 Chambers, H. F. ( 1997 ). Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clinical Microbiology Reviews 10 , 781 –91. 145 Okonogi, K. ( 1990 ). Mechanism of β-lactam-resistance in MRSA. Japanese Journal of Clinical Pathology 38 , 983 –9. 146 Okonogi, K., Noji, Y., Kondo, M., Imada, A. & Yakota, T. ( 1989 ). Emergence of methicillin-resistant clones from cephamycin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 24 , 637 –45. 147 Washio, M. ( 1997 ). Risk factors for methicillin-resistant S. aureus (MRSA) infection in a Japanese elderly care nursing home. Epidemiology and Infection 119 , 285 . 148 Crossley, K., Loesch, D., Landesman, B., Mead, K., Chern, M. & Strate, R. ( 1979 ). An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. Journal of Infectious Diseases 139 , 273 –9. 149 Washio, M., Mizoue, T., Kajioka, T., Yoshimitsu, T., Okayama, M., Hamada, T. et al. ( 1997 ). Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in a Japanese geriatric hospital. Public Health 111 , 187 –90. 150 Peacock, J. E., Marsik, F. J. & Wenzel, R. P. ( 1980 ). Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital. Annals of Internal Medicine 93 , 526 –32. 151 Schentag, J. J., Hyatt, J. M., Carr, J. R., Paladino, J. A., Birmingham, M. C., Zimmer, G. S. et al. ( 1998 ). Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clinical Infectious Diseases 26 , 1204 –14. 152 Kind, A. C., Kestle, D. G., Standiford, H. C., Freeman, P. & Kirby, W. M. M. ( 1968 ). Development of staphylococci crossresistant to cephalexin and methicillin. Antimicrobial Agents and Chemotherapy 8 , 405 –9. 153 Wiedemann, B. ( 1986 ). Selection of β-lactamase producers during cephalosporin and penicillin therapy. Scandinavian Journal of Infectious Diseases 49 , Suppl., 100 –5. 154 Noble, W. C. & Naidoo, J. ( 1978 ). Evolution of antibiotic resistance in Staphylococcus aureus: the role of the skin. British Journal of Dermatology 98 , 481 –9. 155 Forbes, B. A. & Schaberg, D. R. ( 1983 ). Transfer of resistant plasmids from Staphylococcus epidermidis to Staphylococcus aureus: evidence for conjugate exchange of resistance. Journal of Bacteriology 153 , 627 –6. 156 Archer, G. L., Niemeyer, D. M., Thanassi, J. A. & Pucci, M. J. ( 1994 ). Dissemination among staphylococci of DNA sequences associated with methicillin resistance. Antimicrobial Agents and Chemotherapy 38 , 447 –54. 157 Hughes, W. T., Armstrong, D., Bodey, G. & The IDSA Working Group. ( 1990 ). Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 161 , 381 –96. 158 Mannion, P. T., Thom, B. T., Reynolds, C. S. & Strachan, C. J. L. ( 1989 ). The acquisition of antibiotic resistant coagulase-negative staphylococci by aortic graft recipients. Journal of Hospital Infection 14 , 313 –23. 159 Asensio, A., Guerrero, A., Quereda, C., Lizan, M. & Martinez-Ferrer, M. ( 1996 ). Colonization and infection with methicillin- resistant Staphylococcus aureus: associated factors and eradication. Infection Control and Hospital Epidemiology 17 , 20 –8. 160 Hill, D. A., Herford, T. & Parratt, D. ( 1998 ). Antibiotic usage and methicillin-resistant Staphylococci aureus: an analysis of casualty. Journal of Antimicrobial Chemotherapy 42 , 676 –7. 161 Smith, D. W. ( 1999 ). Decreased antimicrobial resistance after changes in antibiotic use. Pharmacotherapy 19 , 129S –132S. 162 Wagenvoort, J. H. T. ( 2000 ). Dutch measures to control MRSA and the expanding European Union. Eurosurveillance 5 , 26 –8. 163 Anonymous. ( 1999 ). Four pediatric deaths from community-acquired MRSA – Minnesota and North Dakota, 1997–1999. MMR Morbidity and Mortality Weekly Report 48 , 707 –10. 164 Acar, J. F., Courvalin, P. & Chabbert, Y. A. ( 1970 ). Methicillin-resistant staphylococcaemia: bacteriological failure of treatment with cephalosporins. Antimicrobial Agents and Chemotherapy 10 , 280 –5. 165 Collins, J. K., Mader, J. T. & Kelly, M. T. ( 1983 ). Resistance of methicillin-resistant Staphylococcus aureus to third-generation cephalosporins. Journal of Infectious Diseases 147 , 591 . 166 Soussy, C. J., Deforges, L., Le Van Thoi, J., Chanal, M., Sirot, D., Acar, J. F. et al. ( 1985 ). In vitro activity of ceftriaxone on hospital bacteria. Results of a multicenter study. Pathologie Biologie 33 , 469 –72. 167 Kernodle, D. S., Classen, D. C., Stratton, D. W. & Kaiser, A. B. ( 1998 ). Association of borderline oxacillin-susceptible strains of Staphylococcus aureus with surgical wound infections. Journal of Clinical Microbiology 36 , 219 –22. 168 Stewart, B., Hall, L., Duke, B. & Ball, D. ( 1997 ). Vancomycin-dependent enterococci: curious phenomenon or serious threat? Journal of Antimicrobial Chemotherapy 40 , 734 –5. 169 Spera, R. V. & Farber, B. F. ( 1994 ). Multi drug resistant Enterococcus faecium. An untreatable nosocomial pathogen. Drug 48 , 678 –88. 170 Bradley, S. J., Wilson, A. L. T., Allen, M. C., Sher, H. A., Goldstone, A. H. & Scott, G. M. ( 1999 ). The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. Journal of Antimicrobial Chemotherapy 43 , 261 –6. 171 Fraise, A. P. ( 1996 ). The treatment and control of vancomycin-resistant enterococci. Journal of Antimicrobial Chemotherapy 38 , 753 –6. 172 Wade, J. J. ( 1995 ). The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents – a preliminary report. Journal of Hospital Infection 30 , Suppl., 483 –93. 173 Chadwick, P. R., Chadwick, C. D. & Oppenheim, B. A. ( 1996 ). Report of a meeting on the epidemiology and control of glycopeptide-resistant enterococci. Journal of Hospital Infection 33 , 83 –92. 174 Van den Bogaard, A. E., Mertens, P., London, N. H. & Stobberingh, E. E. ( 1997 ). High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in The Netherlands: is the addition of antibiotics to animal feeds to blame? Journal of Antimicrobial Chemotherapy 40 , 454 –6. 175 Witte, W. & Klare, I. ( 1995 ). Glycopeptide-resistant Enterococcus faecium outside hospitals: a commentary. Microbial Drug Resistance 1 , 259 –63. 176 Lam, S., Singer, C., Tucci, V., Morthland, V. H., Pfaller, M. A. & Isenverg, H. D. ( 1995 ). The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. American Journal of Infection Control 23 , 170 –80. 177 Watanakunakorn, C. ( 1982 ). Treatment of infections due to methicillin-resistant Staphylococcus aureus. Annals of Internal Medicine 97 , 376 –8. 178 Tedesco, F., Markham, R., Gurwith, M., Christie, D. & Bartlett, J. G. ( 1978 ). Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet ii , 226 –8. 179 Taylor, M. E., Oppenheim, B. A., Chadwick, P. R., Weston, D., Palepou, M. F., Woodford, N. et al. ( 1999 ). Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens. Journal of Hospital Infection 43 , 25 –32. 180 Dukta-Malen, S., Leclerq, R., Coutant, V., Duval, J. & Courvalin, P. ( 1990 ). Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria. Antimicrobial Agents and Chemotherapy 34 , 1875 –9. 181 Kjerulf, A., Pallesen, L. & Westh, H. ( 1996 ). Vancomycin-resistant enterococci at a large university hospital in Denmark. APMIS 104 , 475 –9. 182 Tucci, V., Haran, M. A. & Isenberg, H. D. ( 1997 ). Epidemiology and control of vancomycin-resistant enterococci in an adult and children's hospital. American Journal of Infection Control 25 , 371 –6. 183 Morgan, A. S., Brennan, P. J. & Fishman, N. O. ( 1997 ). Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Annals of Pharmacotherapy 31 , 970 –3. 184 Morris, J. G., Shay, D. K., Hebden, J. N., McCarter, R. J., Perdue, B. E., Jarvis, W. et al. ( 1995 ). Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Annals of Internal Medicine 123 , 250 –9. 185 Wendt, C., Wiesenthal, B., Dietz, E. & Ruden, H. ( 1998 ). Vancomycin-resistant and vancomycin-susceptible enterococci on dry surfaces. Journal of Clinical Microbiology 36 , 3734 –6. 186 Dancer, S. J. ( 1999 ). Mopping up hospital infection. Journal of Hospital Infection 43 , 85 –100. 187 Kawalek, M., Gniadkowski, M. & Hryniewicz, W. ( 2000 ). Outbreak of vancomycin-resistant enterococci in a hospital in Gdansk, Poland, due to horizontal transfer of different Tn1546-like transposon variants and clonal spread of several strains. Journal of Clinical Microbiology 38 , 3317 –22. 188 Rozalska, M., Szewczyk, E. & Piotrowski, A. ( 1993 ). Bacterial flora of the hospital environment: identification, susceptibility to disinfecting agents, antibiotics and chemotherapeutics. Medycyna Doswiadczalna i Mikrobiologia 45 , 373 –8. 189 Noble, W. C. & Virani, Z. ( 1992 ). Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiology Letters 93 , 195 –8. 190 Leclercq, R., Derlot, E., Weber, M., Duval, J. & Courvalin, P. ( 1989 ). Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrobial Agents and Chemotherapy 33 , 10 –5. 191 Boyle-Vavra, S., Daum, R. S., Labischinski, H. & Hiramatsu, K. ( 1998 ). Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. Journal of Antimicrobial Chemotherapy 42 , 199 –209. 192 Hanberger, H., Nilsson, L. E., Nilsson, M. & Maller, R. ( 1991 ). Post-antibiotic effect of β-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. European Journal of Clinical Microbiology and Infectious Diseases 10 , 927 –34. 193 Rolinson, G. N. ( 1998 ). Forty years of β-lactam research. Journal of Antimicrobial Chemotherapy 41 , 589 –603. 194 Rolinson, G. N. ( 1980 ). Effect of β-lactam antibiotics on bacterial cell growth rate. Journal of General Microbiology 120 , 317 –23. 195 Gutmann, l., Vincent, S., Billot-Klein, D., Acar, J. F., Mrena, E. & Williamson, R. ( 1986 ). Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coli by some β-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam). Antimicrobial Agents and Chemotherapy 30 , 906 –12. 196 Gould, I. & Mackenzie, F. M. ( 1997 ). The response of Enterobacteriaceae to β-lactam antibiotics—‘round forms, filaments and the root of all evil’. Journal of Antimicrobial Chemotherapy 40 , 495 –9. 197 Hurley, J. C. ( 1992 ). Antibiotic induced release of endotoxin: a reappraisal. Clinical Infectious Diseases 15 , 840 –54. 198 Dofferhoff, A. S. M., Nijland, J. H., de Vries-Hospers, H. G., Mulder, P. O. M., Weits, J. & Bom, V. J. J. ( 1991 ). Effects of different types and combinations of antimicrobial agents on endotoxin release from Gram-negative bacteria: an in-vitro and in-vivo study. Scandinavian Journal of Infectious Diseases 23 , 745 –54. 199 Geddes, A. M. & Gould, I. M. ( 1993 ). The effects of plasmid-mediated cephalosporinases and endotoxins on septic patients. Serodiagnosis, Immunotherapy, and Infectious Disease 5 , 201 –3. 200 Shenep, J. L., Flynn, P. M., Barrett, F. F., Stidham, G. L. & Westenkirchner, D. F. ( 1988 ). Serial quantitation of endotoxemia and bacteremia during therapy for Gram-negative sepsis. Journal of Infectious Diseases 157 , 565 –8. 201 Periti, P. & Mazzei, T. ( 1999 ). New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. International Journal of Antimicrobial Agents 12 , 97 –105. 202 Finch, R. G. ( 1998 ). Antibiotic resistance. Journal of Antimicrobial Chemotherapy 42 , 125 –8. 203 Ruiz Bremon, A., Ruiz-Tovar, M., Perez Gorricho, B., Diaz de Torres, P. & Lopez Rodriguez, R. ( 2000 ). Non-hospital consumption of antibiotics in Spain: 1987–1997. Journal of Antimicrobial Chemotherapy 45 , 395 –400. 204 McGowan, J. E. ( 1994 ). Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infection Control and Hospital Epidemiology 15 , 478 –83. 205 Shales, D. M., Gerding, D. N., John, J. F., Craig, W. A., Bornstein, D. L., Duncan, R. A. et al. ( 1997 ). Guidelines for the prevention of antimicrobial resistance in hospitals. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance. Infection Control and Hospital Epidemiology 18 , 275 –91. 206 Kolmos, H. J. ( 1999 ). Interaction between the microbiology laboratory and clinician: what the microbiologist can provide. Journal of Hospital Infection, 43 , Suppl., S285 –91. 207 Beam, T. R. ( 1988 ). Recent advances in curtailing costs of antimicrobial agents. The Antimicrobic Newsletter 5 , 17 –21. 208 Gould, I. M. ( 1988 ). Control of antibiotic use in the United Kingdom. Journal of Antimicrobial Chemotherapy 22 , 395 –401. 209 Leistevuo, T., Osterblad, M., Toivonen, P., Kahra, A., Lehtonen, A. & Huovinen, P. ( 1996 ). Colonization of resistant faecal aerobic Gram-negative bacilli among geriatric patients in hospital and the community. Journal of Antimicrobial Chemotherapy 37 , 169 –73. 210 Loefler, I. J. P. ( 1996 ). Microbes, chemotherapy, evolution, and folly. Lancet 348 , 1703 –4. 211 Davey, P., Hudson, S., Ridgway, G. & Reeves, D. ( 1993 ). A survey of undergraduate and continuing medical education and about antimicrobial chemotherapy in the United Kingdom. British Journal of Clinical Pharmacology 36 , 511 –9. 212 Neu, H. C. ( 1990 ). Third generation cephalosporins: safety profiles after 10 years of clinical use. Journal of Clinical Pharmocology 30 , 396 –403. 213 Sanderson, P. J. ( 1993 ). Antimicrobiological prophylaxis in surgery; microbiological factors. Journal of Antimicrobial Chemotherapy 31 , Suppl. B, 1 –9. 214 Livermore, D. ( 2000 ). Epidemiology of antibiotic resistance. Intensive Care Medicine 26 , Suppl. 1, S14 –21. 215 Amyes, S. G. B. & Thomson, C. J. ( 1995 ). Antibiotic resistance in the ICU; the eve of destruction. British Journal of Intensive Care 5 , 263 –7. 216 Desowitz, R. S. (1987). New Guinea Tapeworms and Jewish Grandmothers. W. W. Norton & Co., New York, London. 217 Bernard, G. R., Vincent, J. L., Laterre, P. F., LaRosa, S. P., Dhainaut, J. F., Lopez-Rodriguez, A. et al. ( 2001 ). Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine 344 , 699 –709. 218 Vincent, J. L. ( 2000 ). Afelimomab. International Journal of Clinical Practice 54 , 190 –3. © 2001 The British Society for Antimicrobial Chemotherapy

Journal

Journal of Antimicrobial Chemotherapy – Oxford University Press

Published: Oct 1, 2001

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The problem with cephalosporins

The problem with cephalosporins

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The problem with cephalosporins

The problem with cephalosporins

References (181)

Abstract

Journal

Recommended Articles

There are no references for this article.

Our policy towards the use of cookies